Current therapy for chronic hepatitis C: The role of direct-acting antivirals

Antiviral Research

Volumn 142, Issue , 2017, Pages 83-122

  Li, Guangdi ^a   De Clercq, Erik ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Direct acting antivirals; NS3 4A drugs; NS5A drugs; NS5B drugs

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; CONSENSUS INTERFERON; DACLATASVIR; DANOPREVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR; ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PIBRENTASVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TELAPREVIR; UNINDEXED DRUG; VANIPREVIR; VEDROPREVIR; VELPATASVIR; VOXILAPREVIR; INTERFERON; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3-4A SERINE PROTEASE, HEPATITIS C VIRUS; SERINE PROTEINASE; VIRAL PROTEIN;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DRUG EFFICACY; DRUG POTENCY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HEPACIVIRUS; PATHOGENICITY; TIME FACTOR;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; SERINE PROTEASES; TIME FACTORS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 85016323464     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2017.02.014     Document Type: Review

References (309)

1. AASLD/IDSA HCV Guidance Panel, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
2. Abergel, A., Metivier, S., Samuel, D., Jiang, D., Kersey, K., Pang, P.S., Svarovskaia, E., Knox, S.J., Loustaud-Ratti, V., Asselah, T., Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 64 (2016), 1049–1056.
3. Abergel, A., Asselah, T., Metivier, S., Kersey, K., Jiang, D., Mo, H., Pang, P.S., Samuel, D., Loustaud-Ratti, V., Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect. Dis. 16 (2016), 459–464.
4. Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.P., Agarwal, K., Buggisch, P., Foster, G.R., Brau, N., Buti, M., Jacobson, I.M., Subramanian, G.M., Ding, X., Mo, H., Yang, J.C., Pang, P.S., Symonds, W.T., McHutchison, J.G., Muir, A.J., Mangia, A., Marcellin, P., ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370 (2014), 1889–1898.
5. Afdhal, N., Reddy, K.R., Nelson, D.R., Lawitz, E., Gordon, S.C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., Lalezari, J., Younes, Z.H., Pockros, P.J., Di Bisceglie, A.M., Arora, S., Subramanian, G.M., Zhu, Y., Dvory-Sobol, H., Yang, J.C., Pang, P.S., Symonds, W.T., McHutchison, J.G., Muir, A.J., Sulkowski, M., Kwo, P., ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370 (2014), 1483–1493.
6. Aghemo, A., Rumi, M.G., Colombo, M., Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 7 (2010), 485–494.
7. Ahmed-Belkacem, A., Colliandre, L., Ahnou, N., Nevers, Q., Gelin, M., Bessin, Y., Brillet, R., Cala, O., Douguet, D., Bourguet, W., Krimm, I., Pawlotsky, J.M., Guichou, J.F., Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat. Commun., 7, 2016, 12777.
8. Andreone, P., Colombo, M.G., Enejosa, J.V., Koksal, I., Ferenci, P., Maieron, A., Mullhaupt, B., Horsmans, Y., Weiland, O., Reesink, H.W., Rodrigues, L. Jr., Hu, Y.B., Podsadecki, T., Bernstein, B., ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147 (2014), 359–365 e351.
9. Antonelli, A., Ferri, C., Galeazzi, M., Giannitti, C., Manno, D., Mieli-Vergani, G., Menegatti, E., Olivieri, I., Puoti, M., Palazzi, C., Roccatello, D., Vergani, D., Sarzi-Puttini, P., Atzeni, F., HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Exp. Rheumatol. 26 (2008), S39–S47.
10. Arasappan, A., Bennett, F., Bogen, S.L., Venkatraman, S., Blackman, M., Chen, K.X., Hendrata, S., Huang, Y., Huelgas, R.M., Nair, L., Padilla, A.I., Pan, W., Pike, R., Pinto, P., Ruan, S., Sannigrahi, M., Velazquez, F., Vibulbhan, B., Wu, W., Yang, W., Saksena, A.K., Girijavallabhan, V., Shih, N.Y., Kong, J., Meng, T., Jin, Y., Wong, J., McNamara, P., Prongay, A., Madison, V., Piwinski, J.J., Cheng, K.C., Morrison, R., Malcolm, B., Tong, X., Ralston, R., Njoroge, F.G., Discovery of narlaprevir (SCH 900518): a potent, second generation HCV NS3 serine protease inhibitor. ACS Med. Chem. Lett. 1 (2010), 64–69.
11. Asante-Appiah, E., Liu, R., Curry, S., McMonagle, P., Agrawal, S., Carr, D., Rokosz, L., Lahser, F., Bystol, K., Chase, R., Black, S., Ferrari, E., Ingravallo, P., Chen, S., Tong, L., Yu, W., Kozlowski, J., MK-8408, a Potent and Selective NS5A Inhibitor with a High Genetic Barrier to Resistance and Activity against HCV Genotypes 1-6, Abstr 40. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, Nov 7–11, 2014.
12. Backus, L.I., Belperio, P.S., Shahoumian, T.A., Loomis, T.P., Mole, L.A., Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology 64 (2016), 405–414.
13. Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., Poordad, F., Goodman, Z.D., Sings, H.L., Boparai, N., Burroughs, M., Brass, C.A., Albrecht, J.K., Esteban, R., HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364 (2011), 1207–1217.
14. Bartenschlager, R., Penin, F., Lohmann, V., Andre, P., Assembly of infectious hepatitis C virus particles. Trends Microbiol. 19 (2011), 95–103.
15. Bartenschlager, R., Lohmann, V., Penin, F., The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11 (2013), 482–496.
16. Belema, M., Meanwell, N.A., Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J. Med. Chem. 57 (2014), 5057–5071.
17. Belema, M., Nguyen, V.N., Romine, J.L., St Laurent, D.R., Lopez, O.D., Goodrich, J.T., Nower, P.T., O'Boyle, D.R. 2nd, Lemm, J.A., Fridell, R.A., Gao, M., Fang, H., Krause, R.G., Wang, Y.K., Oliver, A.J., Good, A.C., Knipe, J.O., Meanwell, N.A., Snyder, L.B., Hepatitis C virus NS5A replication complex inhibitors. Part 6: discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons. J. Med. Chem. 57 (2014), 1995–2012.
18. Berger, C., Romero-Brey, I., Radujkovic, D., Terreux, R., Zayas, M., Paul, D., Harak, C., Hoppe, S., Gao, M., Penin, F., Lohmann, V., Bartenschlager, R., Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology 147 (2014), 1094–1105 e1025.
19. Berger, K.L., Sarrazin, C., Nelson, D.R., Scherer, J., Sha, N., Marquis, M., Cote-Martin, A., Vinisko, R., Stern, J.O., Mensa, F.J., Kukolj, G., Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir. PLoS One, 11, 2016, e0160668.
20. Bilello, J.P., Lallos, L.B., McCarville, J.F., La Colla, M., Serra, I., Chapron, C., Gillum, J.M., Pierra, C., Standring, D.N., Seifer, M., In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 58 (2014), 4431–4442.
21. Boson, B., Denolly, S., Turlure, F., Chamot, C., Dreux, M., Cosset, F.L., Daclatasvir prevents Hepatitis C virus infectivity by blocking transfer of the viral genome to assembly sites. Gastroenterology 7 (2017), 895–907 e814.
22. Bourliere, M., Bronowicki, J.P., de Ledinghen, V., Hezode, C., Zoulim, F., Mathurin, P., Tran, A., Larrey, D.G., Ratziu, V., Alric, L., Hyland, R.H., Jiang, D., Doehle, B., Pang, P.S., Symonds, W.T., Subramanian, G.M., McHutchison, J.G., Marcellin, P., Habersetzer, F., Guyader, D., Grange, J.D., Loustaud-Ratti, V., Serfaty, L., Metivier, S., Leroy, V., Abergel, A., Pol, S., Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect. Dis. 15 (2015), 397–404.
23. Brown, A., Hezode, C., Zuckerman, E., Foster, G., Zekry, A., Roberts, S., Howe, A., Durkan, C., Badshah, C., Zhang, B., Robertson, M., Wahl, J., Barr, E., Haber, B., C-SCAPE: efficacy and safety of 12 weeks of grazoprevir ± elbasvir ± ribavirin in patients with HCV GT2, 4, 5, or 6 infection. 50th Annual Meeting of the European Association for the Study of the Liver (EASL), Vienna, Austria, April 2015.
24. de Bruijne, J., Bergmann, J.F., Reesink, H.W., Weegink, C.J., Molenkamp, R., Schinkel, J., Tong, X., Li, J., Treitel, M.A., Hughes, E.A., van Lier, J.J., van Vliet, A.A., Janssen, H.L., de Knegt, R.J., Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology 52 (2010), 1590–1599.
25. Buti, M., Agarwal, K., Horsmans, Y., Sievert, W., Janczewska, E., Zeuzem, S., Nyberg, L., Brown, R.S. Jr., Hezode, C., Rizzetto, M., Parana, R., De Meyer, S., De Masi, R., Luo, D., Bertelsen, K., Witek, J., Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology 146 (2014), 744–753 e743.
26. Cannalire, R., Barreca, M.L., Manfroni, G., Cecchetti, V., A Journey around the medicinal chemistry of hepatitis C virus inhibitors targeting NS4B: from target to preclinical drug candidates. J. Med. Chem. 59 (2016), 16–41.
27. Carlsen, T.H., Pedersen, J., Prentoe, J.C., Giang, E., Keck, Z.Y., Mikkelsen, L.S., Law, M., Foung, S.K., Bukh, J., Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology 60 (2014), 1551–1562.
28. Catanese, M.T., Uryu, K., Kopp, M., Edwards, T.J., Andrus, L., Rice, W.J., Silvestry, M., Kuhn, R.J., Rice, C.M., Ultrastructural analysis of hepatitis C virus particles. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 9505–9510.
29. Charlton, M., Gane, E., Manns, M.P., Brown, R.S. Jr., Curry, M.P., Kwo, P.Y., Fontana, R.J., Gilroy, R., Teperman, L., Muir, A.J., McHutchison, J.G., Symonds, W.T., Brainard, D., Kirby, B., Dvory-Sobol, H., Denning, J., Arterburn, S., Samuel, D., Forns, X., Terrault, N.A., Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
30. Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr., Fried, M.W., Terrault, N.A., O'Leary, J.G., Vargas, H.E., Kuo, A., Schiff, E., Sulkowski, M.S., Gilroy, R., Watt, K.D., Brown, K., Kwo, P., Pungpapong, S., Korenblat, K.M., Muir, A.J., Teperman, L., Fontana, R.J., Denning, J., Arterburn, S., Dvory-Sobol, H., Brandt-Sarif, T., Pang, P.S., McHutchison, J.G., Reddy, K.R., Afdhal, N., SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
31. Chatterji, U., Garcia-Rivera, J.A., Baugh, J., Gawlik, K., Wong, K.A., Zhong, W., Brass, C.A., Naoumov, N.V., Gallay, P.A., The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrob. Agents Chemother. 58 (2014), 3327–3334.
32. Chayama, K., Notsumata, K., Kurosaki, M., Sato, K., Rodrigues, L. Jr., Setze, C., Badri, P., Pilot-Matias, T., Vilchez, R.A., Kumada, H., Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 61 (2015), 1523–1532.
33. Chen, L.Z., Sabo, J.P., Philip, E., Rowland, L., Mao, Y., Latli, B., Ramsden, D., Mandarino, D.A., Sane, R.S., Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor. Antimicrob. Agents Chemother. 59 (2015), 25–37.
34. Cheng, G., Yu, M., Peng, B., Lee, Y.-J., Trejo-Martin, A., Gong, R., Bush, C., Worth, A., Nash, M., Chan, K., Yang, H., Beran, R., Tian, Y., Perry, J., Taylor, J., Yang, C., Paulson, M., Delaney, W., Link, J.O., GS-5816, a second generation hcv ns5a inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. J. Hepatol. 58 (2013), S484–S485.
35. Cheng, G., Tian, Y., Doehle, B., Peng, B., Corsa, A., Lee, Y.J., Gong, R., Yu, M., Han, B., Xu, S., Dvory-Sobol, H., Perron, M., Xu, Y., Mo, H., Pagratis, N., Link, J.O., Delaney, W., Vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob. Agents Chemother. 60 (2016), 1847–1853.
36. Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., Brown, A., Gelson, W.T., MacDonald, D.C., Agarwal, K., Foster, G.R., Irving, W.L., HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 65 (2016), 741–747.
37. Cho, A., Zhang, L., Xu, J., Lee, R., Butler, T., Metobo, S., Aktoudianakis, V., Lew, W., Ye, H., Clarke, M., Doerffler, E., Byun, D., Wang, T., Babusis, D., Carey, A.C., German, P., Sauer, D., Zhong, W., Rossi, S., Fenaux, M., McHutchison, J.G., Perry, J., Feng, J., Ray, A.S., Kim, C.U., Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J. Med. Chem. 57 (2014), 1812–1825.
38. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989), 359–362.
39. De Clercq, E., The race for interferon-free HCV therapies: a snapshot by the spring of 2012. Rev. Med. Virol. 22 (2012), 392–411.
40. De Clercq, E., Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem. Pharmacol. 89 (2014), 441–452.
41. De Clercq, E., Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. Rev. Med. Virol. 25 (2015), 254–267.
42. De Clercq, E., C-nucleosides to Be revisited. J. Med. Chem. 59 (2016), 2301–2311.
43. De Clercq, E., Li, G., Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29 (2016), 695–747.
44. Coburn, C.A., Meinke, P.T., Chang, W., Fandozzi, C.M., Graham, D.J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., McCauley, J.A., Nomeir, A.A., Soll, R.M., Vacca, J.P., Wang, D., Wu, H., Zhong, B., Olsen, D.B., Ludmerer, S.W., Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 8 (2013), 1930–1940.
45. Coelmont, L., Hanoulle, X., Chatterji, U., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., Vandamme, A.M., Bartenschlager, R., Gallay, P., Lippens, G., Neyts, J., DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One, 5, 2010, e13687.
46. Coilly, A., Fougerou-Leurent, C., de Ledinghen, V., Houssel-Debry, P., Duvoux, C., Di Martino, V., Radenne, S., Kamar, N., D'Alteroche, L., Leroy, V., Canva, V., Lebray, P., Moreno, C., Dumortier, J., Silvain, C., Besch, C., Perre, P., Botta-Fridlund, D., Anty, R., Francoz, C., Abergel, A., Debette-Gratien, M., Conti, F., Habersetzer, F., Rohel, A., Rossignol, E., Danjou, H., Roque-Afonso, A.M., Samuel, D., Duclos-Vallee, J.C., Pageaux, G.P., ANRS C023 CUPILT study group. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - the ANRS CUPILT study. J. Hepatol. 65 (2016), 711–718.
47. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., Foschi, F.G., Lenzi, M., Mazzella, G., Verucchi, G., Andreone, P., Brillanti, S., Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J. Hepatol. 65 (2016), 727–733.
48. Court, J.J., Poisson, C., Ardzinski, A., Bilimoria, D., Chan, L., Chandupatla, K., Chauret, N., Collier, P.N., Das, S.K., Denis, F., Dorsch, W., Iyer, G., Lauffer, D., L'Heureux, L., Li, P., Luisi, B.S., Mani, N., Nanthakumar, S., Nicolas, O., Rao, B.G., Ronkin, S., Selliah, S., Shawgo, R.S., Tang, Q., Waal, N.D., Yannopoulos, C.G., Green, J., Discovery of novel thiophene-based, thumb pocket 2 allosteric inhibitors of the hepatitis C NS5B polymerase with improved potency and physicochemical profiles. J. Med. Chem. 59 (2016), 6293–6302.
49. Cox, A.L., MEDICINE. Global control of hepatitis C virus. Science 349 (2015), 790–791.
50. Cummings, M.D., Lin, T.I., Hu, L., Tahri, A., McGowan, D., Amssoms, K., Last, S., Devogelaere, B., Rouan, M.C., Vijgen, L., Berke, J.M., Dehertogh, P., Fransen, E., Cleiren, E., van der Helm, L., Fanning, G., Nyanguile, O., Simmen, K., Van Remoortere, P., Raboisson, P., Vendeville, S., Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem. 57 (2014), 1880–1892.
51. Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., Reddy, K.R., Lawitz, E., Flamm, S.L., Schiano, T., Teperman, L., Fontana, R., Schiff, E., Fried, M., Doehle, B., An, D., McNally, J., Osinusi, A., Brainard, D.M., McHutchison, J.G., Brown, R.S. Jr., Charlton, M., Investigators A-. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 373 (2015), 2618–2628.
52. Cuypers, L., Li, G., Libin, P., Piampongsant, S., Vandamme, A.-M., Theys, K., Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance. Viruses 7 (2015), 5018–5039.
53. Cuypers, L., Ceccherini-Silberstein, F., Van Laethem, K., Li, G., Vandamme, A.M., Rockstroh, J.K., Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev. Med. Virol. 26 (2016), 408–434.
54. DeGoey, D.A., Randolph, J.T., Liu, D., Pratt, J., Hutchins, C., Donner, P., Krueger, A.C., Matulenko, M., Patel, S., Motter, C.E., Nelson, L., Keddy, R., Tufano, M., Caspi, D.D., Krishnan, P., Mistry, N., Koev, G., Reisch, T.J., Mondal, R., Pilot-Matias, T., Gao, Y., Beno, D.W., Maring, C.J., Molla, A., Dumas, E., Campbell, A., Williams, L., Collins, C., Wagner, R., Kati, W.M., Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J. Med. Chem. 57 (2014), 2047–2057.
55. Deterding, K., Spinner, C.D., Schott, E., Welzel, T.M., Gerken, G., Klinker, H., Spengler, U., Wiegand, J., Zur Wiesch, J.S., Pathil, A., Cornberg, M., Umgelter, A., Zollner, C., Zeuzem, S., Papkalla, A., Weber, K., Hardtke, S., von der Leyen, H., Koch, A., von Witzendorff, D., Manns, M.P., Wedemeyer, H., HepNet Acute HCVIVSG. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect. Dis. 17 (2017), 215–222.
56. Disease, G.B.D., Injury, I., Prevalence, C., Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1545–1602.
57. Dore, G.J., Conway, B., Luo, Y., Janczewska, E., Knysz, B., Liu, Y., Streinu-Cercel, A., Caruntu, F.A., Curescu, M., Skoien, R., Ghesquiere, W., Mazur, W., Soza, A., Fuster, F., Greenbloom, S., Motoc, A., Arama, V., Shaw, D., Tornai, I., Sasadeusz, J., Dalgard, O., Sullivan, D., Liu, X., Kapoor, M., Campbell, A., Podsadecki, T., Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J. Hepatol. 64 (2016), 19–28.
58. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C.Y., Conway, B., Grebely, J., Howe, A.Y., Gendrano, I.N., Chen, E., Huang, H.C., Dutko, F.J., Nickle, D.C., Nguyen, B.Y., Wahl, J., Barr, E., Robertson, M.N., Platt, H.L., C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann. Intern Med. 165 (2016), 625–634.
59. Doss, W., Shiha, G., Hassany, M., Soliman, R., Fouad, R., Khairy, M., Samir, W., Hammad, R., Kersey, K., Jiang, D., Doehle, B., Knox, S.J., Massetto, B., McHutchison, J.G., Esmat, G., Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J. Hepatol. 63 (2015), 581–585.
60. Dubuisson, J., Cosset, F.L., Virology and cell biology of the hepatitis C virus life cycle: an update. J. Hepatol. 61 (2014), S3–S13.
61. Egger, D., Wolk, B., Gosert, R., Bianchi, L., Blum, H.E., Moradpour, D., Bienz, K., Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76 (2002), 5974–5984.
62. Ehteshami, M., Tao, S., Ozturk, T., Zhou, L., Cho, J.H., Zhang, H., Amiralaei, S., Shelton, J.R., Lu, X., Khalil, A., Domaoal, R.A., Stanton, R.A., Suesserman, J.E., Lin, B., Lee, S.S., Amblard, F., Whitaker, T., Coats, S.J., Schinazi, R.F., Biochemical characterization of the active anti-hepatitis C virus metabolites of 2,6-diaminopurine ribonucleoside prodrug compared to sofosbuvir and BMS-986094. Antimicrob. Agents Chemother. 60 (2016), 4659–4669.
63. El-Khayat, H.R., Fouad, Y.M., Maher, M., El-Amin, H., Muhammed, H., Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut, 2016, 10.1136/gutjnl-2016–312012.
64. El-Serag, H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 (2012), 1264–1273.
65. Elsebai, M.F., Koutsoudakis, G., Saludes, V., Perez-Vilaro, G., Turpeinen, A., Mattila, S., Pirttila, A.M., Fontaine-Vive, F., Mehiri, M., Meyerhans, A., Diez, J., Pan-genotypic hepatitis C virus inhibition by natural products derived from the wild Egyptian artichoke. J. Virol. 90 (2015), 1918–1930.
66. Eltahla, A.A., Tay, E., Douglas, M.W., White, P.A., Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. Antimicrob. Agents Chemother. 58 (2014), 7215–7224.
67. Esser-Nobis, K., Schmidt, J., Nitschke, K., Neumann-Haefelin, C., Thimme, R., Lohmann, V., The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cell activation. J. Hepatol. 64 (2016), 1305–1314.
68. European Association for Study of Liver, EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 63 (2015), 199–236.
69. Everson, G.T., Sims, K.D., Rodriguez-Torres, M., Hezode, C., Lawitz, E., Bourliere, M., Loustaud-Ratti, V., Rustgi, V., Schwartz, H., Tatum, H., Marcellin, P., Pol, S., Thuluvath, P.J., Eley, T., Wang, X., Huang, S.P., McPhee, F., Wind-Rotolo, M., Chung, E., Pasquinelli, C., Grasela, D.M., Gardiner, D.F., Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146 (2014), 420–429.
70. Everson, G.T., Towner, W.J., Davis, M.N., Wyles, D.L., Nahass, R.G., Thuluvath, P.J., Etzkorn, K., Hinestrosa, F., Tong, M., Rabinovitz, M., McNally, J., Brainard, D.M., Han, L., Doehle, B., McHutchison, J.G., Morgan, T., Chung, R.T., Tran, T.T., Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann. Intern Med. 163 (2015), 818–826.
71. Everson, G.T., Sims, K.D., Thuluvath, P.J., Lawitz, E., Hassanein, T., Rodriguez-Torres, M., Desta, T., Hawkins, T., Levin, J.M., Hinestrosa, F., Rustgi, V., Schwartz, H., Younossi, Z., Webster, L., Gitlin, N., Eley, T., Huang, S.P., McPhee, F., Grasela, D.M., Gardiner, D.F., Daclatasvir + asunaprevir + beclabuvir +/- ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 36 (2016), 189–197.
72. Feld, J.J., Kowdley, K.V., Coakley, E., Sigal, S., Nelson, D.R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., DaSilva-Tillmann, B., Larsen, L., Podsadecki, T., Bernstein, B., Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370 (2014), 1594–1603.
73. Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., Abergel, A., Mangia, A., Lai, C.L., Chan, H.L., Mazzotta, F., Moreno, C., Yoshida, E., Shafran, S.D., Towner, W.J., Tran, T.T., McNally, J., Osinusi, A., Svarovskaia, E., Zhu, Y., Brainard, D.M., McHutchison, J.G., Agarwal, K., Zeuzem, S., Investigators A-. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N. Engl. J. Med. 373 (2015), 2599–2607.
74. Feld, J.J., Jacobson, I.M., Jensen, D.M., Foster, G.R., Pol, S., Tam, E., Jablkowski, M., Berak, H., Vierling, J.M., Yoshida, E.M., Perez-Gomez, H.R., Scalori, A., Hooper, G.J., Tavel, J.A., Navarro, M.T., Shahdad, S., Kulkarni, R., Le Pogam, S., Najera, I., Eng, S., Lim, C.Y., Shulman, N.S., Yetzer, E.S., Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J. Hepatol. 62 (2015), 294–302.
75. Feld, J.J., Maan, R., Zeuzem, S., Kuo, A., Nelson, D.R., Di Bisceglie, A.M., Manns, M.P., Sherman, K., Frazier, L.M., Sterling, R., Mailliard, M., Schmidt, M., Akushevich, L., Vainorius, M., Fried, M.W., Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin. Infect. Dis. 63 (2016), 776–783.
76. Feld, J.J., Moreno, C., Trinh, R., Tam, E., Bourgeois, S., Horsmans, Y., Elkhashab, M., Bernstein, D.E., Younes, Z., Reindollar, R.W., Larsen, L., Fu, B., Howieson, K., Polepally, A.R., Pangerl, A., Shulman, N.S., Poordad, F., Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J. Hepatol. 64 (2016), 301–307.
77. Felmlee, D.J., Coilly, A., Chung, R.T., Samuel, D., Baumert, T.F., New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect. Dis. 16 (2016), 735–745.
78. Fenaux, M., Eng, S., Leavitt, S.A., Lee, Y.J., Mabery, E.M., Tian, Y., Byun, D., Canales, E., Clarke, M.O., Doerffler, E., Lazerwith, S.E., Lew, W., Liu, Q., Mertzman, M., Morganelli, P., Xu, L., Ye, H., Zhang, J., Matles, M., Murray, B.P., Mwangi, J., Zhang, J., Hashash, A., Krawczyk, S.H., Bidgood, A.M., Appleby, T.C., Watkins, W.J., Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 57 (2013), 804–810.
79. Feng, J.Y., Cheng, G., Perry, J., Barauskas, O., Xu, Y., Fenaux, M., Eng, S., Tirunagari, N., Peng, B., Yu, M., Tian, Y., Lee, Y.J., Stepan, G., Lagpacan, L.L., Jin, D., Hung, M., Ku, K.S., Han, B., Kitrinos, K., Perron, M., Birkus, G., Wong, K.A., Zhong, W., Kim, C.U., Carey, A., Cho, A., Ray, A.S., Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob. Agents Chemother. 58 (2014), 1930–1942.
80. Ferenci, P., Treatment of hepatitis C in difficult-to-treat patients. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 284–292.
81. Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R.T., Tsai, N., Nyberg, A., Box, T.D., Younes, Z., Enayati, P., Green, S., Baruch, Y., Bhandari, B.R., Caruntu, F.A., Sepe, T., Chulanov, V., Janczewska, E., Rizzardini, G., Gervain, J., Planas, R., Moreno, C., Hassanein, T., Xie, W., King, M., Podsadecki, T., Reddy, K.R., PEARL-III Study, PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370 (2014), 1983–1992.
82. Ferenci, P., Kozbial, K., Mandorfer, M., Hofer, H., HCV targeting of patients with cirrhosis. J. Hepatol. 63 (2015), 1015–1022.
83. Flamm, S.L., Lawitz, E., Jacobson, I., Bourliere, M., Hezode, C., Vierling, J.M., Bacon, B.R., Niederau, C., Sherman, M., Goteti, V., Sings, H.L., Barnard, R.O., Howe, J.A., Pedicone, L.D., Burroughs, M.H., Brass, C.A., Albrecht, J.K., Poordad, F., Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin. Gastroenterol. Hepatol. 11 (2013), 81–87.
84. Forestier, N., Larrey, D., Marcellin, P., Guyader, D., Patat, A., Rouzier, R., Smith, P.F., Qin, X., Lim, S., Bradford, W., Porter, S., Seiwert, S.D., Zeuzem, S., Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C. J. Infect. Dis. 204 (2011), 601–608.
85. Forns, X., Lawitz, E., Zeuzem, S., Gane, E., Bronowicki, J.P., Andreone, P., Horban, A., Brown, A., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., Scott, J., De La Rosa, G., Kalmeijer, R., Sinha, R., Beumont-Mauviel, M., Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 146 (2014), 1669–1679 e1663.
86. Forns, X., Charlton, M., Denning, J., McHutchison, J.G., Symonds, W.T., Brainard, D., Brandt-Sarif, T., Chang, P., Kivett, V., Castells, L., Prieto, M., Fontana, R.J., Baumert, T.F., Coilly, A., Londono, M.C., Habersetzer, F., Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61 (2015), 1485–1494.
87. Forns, X., Gordon, S.C., Zuckerman, E., Lawitz, E., Calleja, J.L., Hofer, H., Gilbert, C., Palcza, J., Howe, A.Y., DiNubile, M.J., Robertson, M.N., Wahl, J., Barr, E., Buti, M., Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J. Hepatol. 63 (2015), 564–572.
88. Foster, T.L., Thompson, G.S., Kalverda, A.P., Kankanala, J., Bentham, M., Wetherill, L.F., Thompson, J., Barker, A.M., Clarke, D., Noerenberg, M., Pearson, A.R., Rowlands, D.J., Homans, S.W., Harris, M., Foster, R., Griffin, S., Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release. Hepatology 59 (2014), 408–422.
89. Foster, G.R., Pianko, S., Brown, A., Forton, D., Nahass, R.G., George, J., Barnes, E., Brainard, D.M., Massetto, B., Lin, M., Han, B., McHutchison, J.G., Subramanian, G.M., Cooper, C., Agarwal, K., Boson Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
90. Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M.L., Cooper, C., Towner, W.J., Conway, B., Ruane, P., Bourliere, M., Asselah, T., Berg, T., Zeuzem, S., Rosenberg, W., Agarwal, K., Stedman, C.A., Mo, H., Dvory-Sobol, H., Han, L., Wang, J., McNally, J., Osinusi, A., Brainard, D.M., McHutchison, J.G., Mazzotta, F., Tran, T.T., Gordon, S.C., Patel, K., Reau, N., Mangia, A., Sulkowski, M., ASTRAL-2 Investigators, ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N. Engl. J. Med. 373 (2015), 2608–2617.
91. Fried, M.W., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P., Jacobson, I., Marcellin, P., Manns, M., Nikitin, I., Poordad, F., Sherman, M., Zeuzem, S., Scott, J., Gilles, L., Lenz, O., Peeters, M., Sekar, V., De Smedt, G., Beumont-Mauviel, M., Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 58 (2013), 1918–1929.
92. Fu, J., Tjandra, M., Becker, C., Bednarczyk, D., Capparelli, M., Elling, R., Hanna, I., Fujimoto, R., Furegati, M., Karur, S., Kasprzyk, T., Knapp, M., Leung, K., Li, X., Lu, P., Mergo, W., Miault, C., Ng, S., Parker, D., Peng, Y., Roggo, S., Rivkin, A., Simmons, R.L., Wang, M., Wiedmann, B., Weiss, A.H., Xiao, L., Xie, L., Xu, W., Yifru, A., Yang, S., Zhou, B., Sweeney, Z.K., Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition. J. Med. Chem. 57 (2014), 8503–8516.
93. Gambato, M., Lens, S., Navasa, M., Forns, X., Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J. Hepatol. 61 (2014), S120–S131.
94. Gane, E.J., Roberts, S.K., Stedman, C.A., Angus, P.W., Ritchie, B., Elston, R., Ipe, D., Morcos, P.N., Baher, L., Najera, I., Chu, T., Lopatin, U., Berrey, M.M., Bradford, W., Laughlin, M., Shulman, N.S., Smith, P.F., Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376 (2010), 1467–1475.
95. Gane, E.J., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., Zhang, Y., Sampeur, P., Najera, I., Smith, P., Shulman, N.S., Tran, J.Q., Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J. Hepatol. 55 (2011), 972–979.
96. Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., Hindes, R.G., Berrey, M.M., Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368 (2013), 34–44.
97. Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E.S., Pang, P.S., Symonds, W.T., Once Daily Sofosbuvir/Ledipasvir Fixed-dose Combination with or without Ribavirin: Data from the ELECTRON Trials, Abstr 64rd Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC Nov 1-5 2013. 2013.
98. Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Subramanian, G.M., Symonds, W.T., McHutchison, J.G., Pang, P.S., Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 146 (2014), 736–743 e731.
99. Gane, E.J., Rouzier, R., Wiercinska-Drapalo, A., Larrey, D.G., Morcos, P.N., Brennan, B.J., Le Pogam, S., Najera, I., Petric, R., Tran, J.Q., Kulkarni, R., Zhang, Y., Smith, P., Yetzer, E.S., Shulman, N.S., Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob. Agents Chemother. 58 (2014), 1136–1145.
100. Gane, E.J., Hyland, R.H., An, D., Svarovskaia, E., Pang, P.S., Brainard, D., Stedman, C.A., Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149 (2015), 1454–1461 e1451.
101. Gane, E., Kowdley, K.V., Pound, D., Stedman, C.A., Davis, M., Etzkorn, K., Gordon, S.C., Bernstein, D., Everson, G., Rodriguez-Torres, M., Tsai, N., Khalid, O., Yang, J.C., Lu, S., Dvory-Sobol, H., Stamm, L.M., Brainard, D.M., McHutchison, J.G., Tong, M., Chung, R.T., Beavers, K., Poulos, J.E., Kwo, P.Y., Nguyen, M.H., Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology 151 (2016), 902–909.
102. Gane, E.J., Schwabe, C., Hyland, R.H., Yang, Y., Svarovskaia, E., Stamm, L.M., Brainard, D.M., McHutchison, J.G., Stedman, C.A., Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology 151 (2016), 448–456.
103. Gane, E., Poordad, F., Wang, S., Asatryan, A., Kwo, P.Y., Lalezari, J., Wyles, D.L., Hassanein, T., Aguilar, H., Maliakkal, B., Liu, R., Lin, C.W., Ng, T.I., Kort, J., Mensa, F.J., High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 151 (2016), 651–659 e651.
104. Gane, E.J., Pianko, S., Roberts, S.K., Thompson, A.J., Zeuzem, S., Zuckerman, E., Ari, Z.B., Foster, G.R., Agarwal, K., Laursen, A.L., Gertoft, J., Gao, W., Huang, H.-C., Fitzgerald, B., Li, J.J., Wan, S., Dutko, F., Nguyen, B.-Y.T., Wahl, J., Barr, E., Butterton, J.R., Esteban, R., High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies, Abstr 38. 2016, EASL - European Association for the Study of the Liver, Barcelona April 14–17.
105. Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O'Boyle, D.R. 2nd, Lemm, J.A., Wang, C., Knipe, J.O., Chien, C., Colonno, R.J., Grasela, D.M., Meanwell, N.A., Hamann, L.G., Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465 (2010), 96–100.
106. Ge, P.S., Runyon, B.A., Treatment of patients with cirrhosis. N. Engl. J. Med. 375 (2016), 767–777.
107. Gentile, I., Buonomo, A.R., Zappulo, E., Borgia, G., Discontinued drugs in 2012-2013: hepatitis C virus infection. Expert Opin. Investig. Drugs 24 (2015), 239–251.
108. Gentles, R.G., Ding, M., Bender, J.A., Bergstrom, C.P., Grant-Young, K., Hewawasam, P., Hudyma, T., Martin, S., Nickel, A., Regueiro-Ren, A., Tu, Y., Yang, Z., Yeung, K.S., Zheng, X., Chao, S., Sun, J.H., Beno, B.R., Camac, D.M., Chang, C.H., Gao, M., Morin, P.E., Sheriff, S., Tredup, J., Wan, J., Witmer, M.R., Xie, D., Hanumegowda, U., Knipe, J., Mosure, K., Santone, K.S., Parker, D.D., Zhuo, X., Lemm, J., Liu, M., Pelosi, L., Rigat, K., Voss, S., Wang, Y., Wang, Y.K., Colonno, R.J., Gao, M., Roberts, S.B., Gao, Q., Ng, A., Meanwell, N.A., Kadow, J.F., Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem. 57 (2014), 1855–1879.
109. Gosert, R., Egger, D., Lohmann, V., Bartenschlager, R., Blum, H.E., Bienz, K., Moradpour, D., Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 77 (2003), 5487–5492.
110. Gotte, M., Feld, J.J., Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 338–351.
111. Hamed, M.R., Brown, R.J., Zothner, C., Urbanowicz, R.A., Mason, C.P., Krarup, A., McClure, C.P., Irving, W.L., Ball, J.K., Harris, M., Hickling, T.P., Tarr, A.W., Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. J. Innate Immun. 6 (2014), 676–684.
112. Harper, S., McCauley, J.A., Rudd, M.T., Ferrara, M., DiFilippo, M., Crescenzi, B., Koch, U., Petrocchi, A., Holloway, M.K., Butcher, J.W., Romano, J.J., Bush, K.J., Gilbert, K.F., McIntyre, C.J., Nguyen, K.T., Nizi, E., Carroll, S.S., Ludmerer, S.W., Burlein, C., DiMuzio, J.M., Graham, D.J., McHale, C.M., Stahlhut, M.W., Olsen, D.B., Monteagudo, E., Cianetti, S., Giuliano, C., Pucci, V., Trainor, N., Fandozzi, C.M., Rowley, M., Coleman, P.J., Vacca, J.P., Summa, V., Liverton, N.J., Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med. Chem. Lett. 3 (2012), 332–336.
113. Hassanein, T., Sims, K.D., Bennett, M., Gitlin, N., Lawitz, E., Nguyen, T., Webster, L., Younossi, Z., Schwartz, H., Thuluvath, P.J., Zhou, H., Rege, B., McPhee, F., Zhou, N., Wind-Rotolo, M., Chung, E., Griffies, A., Grasela, D.M., Gardiner, D.F., A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J. Hepatol. 62 (2015), 1204–1206.
114. Hayashi, N., Izumi, N., Kumada, H., Okanoue, T., Tsubouchi, H., Yatsuhashi, H., Kato, M., Ki, R., Komada, Y., Seto, C., Goto, S., Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J. Hepatol. 61 (2014), 219–227.
115. He, S., Lin, B., Chu, V., Hu, Z., Hu, X., Xiao, J., Wang, A.Q., Schweitzer, C.J., Li, Q., Imamura, M., Hiraga, N., Southall, N., Ferrer, M., Zheng, W., Chayama, K., Marugan, J.J., Liang, T.J., Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci. Transl. Med., 7, 2015 282ra249.
116. He, S., Xiao, J., Dulcey, A.E., Lin, B., Rolt, A., Hu, Z., Hu, X., Wang, A.Q., Xu, X., Southall, N., Ferrer, M., Zheng, W., Liang, T.J., Marugan, J.J., Discovery, optimization, and characterization of novel chlorcyclizine derivatives for the treatment of hepatitis C virus infection. J. Med. Chem. 59 (2016), 841–853.
117. Hezode, C., Fontaine, H., Dorival, C., Zoulim, F., Larrey, D., Canva, V., De Ledinghen, V., Poynard, T., Samuel, D., Bourliere, M., Alric, L., Raabe, J.J., Zarski, J.P., Marcellin, P., Riachi, G., Bernard, P.H., Loustaud-Ratti, V., Chazouilleres, O., Abergel, A., Guyader, D., Metivier, S., Tran, A., Di Martino, V., Causse, X., Dao, T., Lucidarme, D., Portal, I., Cacoub, P., Gournay, J., Grando-Lemaire, V., Hillon, P., Attali, P., Fontanges, T., Rosa, I., Petrov-Sanchez, V., Barthe, Y., Pawlotsky, J.M., Pol, S., Carrat, F., Bronowicki, J.P., Cupic Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147 (2014), 132–142 e134.
118. Hezode, C., Asselah, T., Reddy, K.R., Hassanein, T., Berenguer, M., Fleischer-Stepniewska, K., Marcellin, P., Hall, C., Schnell, G., Pilot-Matias, T., Mobashery, N., Redman, R., Vilchez, R.A., Pol, S., Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385 (2015), 2502–2509.
119. Hezode, C., Chevaliez, S., Scoazec, G., Soulier, A., Varaut, A., Bouvier-Alias, M., Ruiz, I., Roudot-Thoraval, F., Mallat, A., Feray, C., Pawlotsky, J.M., Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology 63 (2016), 1809–1816.
120. Ho, S.B., Monto, A., Peyton, A., Kaplan, D.E., Byrne, S., Moon, S., Copans, A., Rossaro, L., Roy, A., Le, H., Dvory-Sobol, H., Zhu, Y., Brainard, D.M., Guyer, W., Shaikh, O., Fuchs, M., Morgan, T.R., Valor study team. Efficacy of sofosbuvir plus ribavirin in veterans with hepatitis C virus genotype 2 infection, compensated cirrhosis, and multiple comorbidities. Clin. Gastroenterol. Hepatol. 15 (2017), 282–288.
121. Ioannou, G.N., Beste, L.A., Chang, M.F., Green, P.K., Lowy, E., Tsui, J.I., Su, F., Berry, K., Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology 151 (2016), 457–471 e455.
122. Isakov, V., Koloda, D., Tikhonova, N., Kikalishvili, T., Krasavina, E., Lekishvili, K., Malaya, I., Ryska, M., Samsonov, M., Tolkacheva, V., Pharmacokinetics of new HCV NS3 protease inhibitor narlaprevir following single dose use with or without ritonavir in patients with liver cirrhosis. Antimicrob. Agents Chemother. 60 (2016), 7098–7104.
123. Ivachtchenko, A.V., Mitkin, O.D., Yamanushkin, P.M., Kuznetsova, I.V., Bulanova, E.A., Shevkun, N.A., Koryakova, A.G., Karapetian, R.N., Bichko, V.V., Trifelenkov, A.S., Kravchenko, D.V., Vostokova, N.V., Veselov, M.S., Chufarova, N.V., Ivanenkov, Y.A., Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J. Med. Chem. 57 (2014), 7716–7730.
124. Izumi, N., Hayashi, N., Kumada, H., Okanoue, T., Tsubouchi, H., Yatsuhashi, H., Kato, M., Ki, R., Komada, Y., Seto, C., Goto, S., Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J. Gastroenterol. 49 (2014), 941–953.
125. Jacobson, I.M., Gordon, S.C., Kowdley, K.V., Yoshida, E.M., Rodriguez-Torres, M., Sulkowski, M.S., Shiffman, M.L., Lawitz, E., Everson, G., Bennett, M., Schiff, E., Al-Assi, M.T., Subramanian, G.M., An, D., Lin, M., McNally, J., Brainard, D., Symonds, W.T., McHutchison, J.G., Patel, K., Feld, J., Pianko, S., Nelson, D.R., Study, P., Study, F., Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368 (2013), 1867–1877.
126. Jacobson, I.M., Dore, G.J., Foster, G.R., Fried, M.W., Radu, M., Rafalsky, V.V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Scott, J., Sinha, R., Beumont-Mauviel, M., Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384 (2014), 403–413.
127. Jiang, Y., Andrews, S.W., Condroski, K.R., Buckman, B., Serebryany, V., Wenglowsky, S., Kennedy, A.L., Madduru, M.R., Wang, B., Lyon, M., Doherty, G.A., Woodard, B.T., Lemieux, C., Geck Do, M., Zhang, H., Ballard, J., Vigers, G., Brandhuber, B.J., Stengel, P., Josey, J.A., Beigelman, L., Blatt, L., Seiwert, S.D., Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J. Med. Chem. 57 (2014), 1753–1769.
128. Jiang, M., Zhang, E.Z., Ardzinski, A., Tigges, A., Davis, A., Sullivan, J.C., Nelson, M., Spanks, J., Dorrian, J., Nicolas, O., Bartels, D.J., Rao, B.G., Rijnbrand, R., Kieffer, T.L., Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. Antimicrob. Agents Chemother. 58 (2014), 5456–5465.
129. Jonckers, T.H., Tahri, A., Vijgen, L., Berke, J.M., Lachau-Durand, S., Stoops, B., Snoeys, J., Leclercq, L., Tambuyzer, L., Lin, T.I., Simmen, K., Raboisson, P., Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]d ioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-cyclic phosphate ester prodrug of 2'-deoxy-2'-spirooxetane uridine triphosphate useful for HCV inhibition. J. Med. Chem. 59 (2016), 5790–5798.
130. Kakarla, R., Liu, J., Naduthambi, D., Chang, W., Mosley, R.T., Bao, D., Steuer, H.M., Keilman, M., Bansal, S., Lam, A.M., Seibel, W., Neilson, S., Furman, P.A., Sofia, M.J., Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives. J. Med. Chem. 57 (2014), 2136–2160.
131. Kati, W., Koev, G., Irvin, M., Beyer, J., Liu, Y., Krishnan, P., Reisch, T., Mondal, R., Wagner, R., Molla, A., Maring, C., Collins, C., In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob. Agents Chemother. 59 (2015), 1505–1511.
132. Kazmierski, W.M., Maynard, A., Duan, M., Baskaran, S., Botyanszki, J., Crosby, R., Dickerson, S., Tallant, M., Grimes, R., Hamatake, R., Leivers, M., Roberts, C.D., Walker, J., Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound. J. Med. Chem. 57 (2014), 2058–2073.
133. Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., O'Malley, E.T., Harbeson, S.L., Rice, C.M., Murcko, M.A., Caron, P.R., Thomson, J.A., Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87 (1996), 343–355.
134. Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E.G., Barrett, L.L., Bon, D., Marti, M.M., Silk, R., Kotb, C., Gross, C., Jolley, T.A., Sidharthan, S., Petersen, T., Townsend, K., Egerson, D., Kapoor, R., Spurlin, E., Sneller, M., Proschan, M., Herrmann, E., Kwan, R., Teferi, G., Talwani, R., Diaz, G., Kleiner, D.E., Wood, B.J., Chavez, J., Abbott, S., Symonds, W.T., Subramanian, G.M., Pang, P.S., McHutchison, J., Polis, M.A., Fauci, A.S., Masur, H., Kottilil, S., Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385 (2015), 1107–1113.
135. Kohli, A., Kapoor, R., Sims, Z., Nelson, A., Sidharthan, S., Lam, B., Silk, R., Kotb, C., Gross, C., Teferi, G., Sugarman, K., Pang, P.S., Osinusi, A., Polis, M.A., Rustgi, V., Masur, H., Kottilil, S., Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect. Dis. 15 (2015), 1049–1054.
136. Kohli, A., Kattakuzhy, S., Sidharthan, S., Nelson, A., McLaughlin, M., Seamon, C., Wilson, E., Meissner, E.G., Sims, Z., Silk, R., Gross, C., Akoth, E., Tang, L., Price, A., Jolley, T.A., Emmanuel, B., Proschan, M., Teferi, G., Chavez, J., Abbott, S., Osinusi, A., Mo, H., Polis, M.A., Masur, H., Kottilil, S., Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. Ann. Intern Med. 163 (2015), 899–907.
137. Komatsu, T.E., Boyd, S., Sherwat, A., Tracy, L., Naeger, L.K., O'Rear, J.J., Harrington, P.R., Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology 152 (2017), 586–597.
138. Koutsoudakis, G., Romero-Brey, I., Berger, C., Perez-Vilaro, G., Monteiro Perin, P., Vondran, F.W., Kalesse, M., Harmrolfs, K., Muller, R., Martinez, J.P., Pietschmann, T., Bartenschlager, R., Bronstrup, M., Meyerhans, A., Diez, J., Soraphen A: a broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. J. Hepatol. 63 (2015), 813–821.
139. Kovackova, S., Chang, L., Bekerman, E., Neveu, G., Barouch-Bentov, R., Chaikuad, A., Heroven, C., Sala, M., De Jonghe, S., Knapp, S., Einav, S., Herdewijn, P., Selective inhibitors of cyclin G associated kinase (GAK) as anti-hepatitis C agents. J. Med. Chem. 58 (2015), 3393–3410.
140. Kowdley, K.V., Lawitz, E., Crespo, I., Hassanein, T., Davis, M.N., DeMicco, M., Bernstein, D.E., Afdhal, N., Vierling, J.M., Gordon, S.C., Anderson, J.K., Hyland, R.H., Dvory-Sobol, H., An, D., Hindes, R.G., Albanis, E., Symonds, W.T., Berrey, M.M., Nelson, D.R., Jacobson, I.M., Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 381 (2013), 2100–2107.
141. Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E., Shiffman, M.L., Schiff, E., Ghalib, R., Ryan, M., Rustgi, V., Chojkier, M., Herring, R., Di Bisceglie, A.M., Pockros, P.J., Subramanian, G.M., An, D., Svarovskaia, E., Hyland, R.H., Pang, P.S., Symonds, W.T., McHutchison, J.G., Muir, A.J., Pound, D., Fried, M.W., ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370 (2014), 1879–1888.
142. Kowdley, K.V., Lawitz, E., Poordad, F., Cohen, D.E., Nelson, D.R., Zeuzem, S., Everson, G.T., Kwo, P., Foster, G.R., Sulkowski, M.S., Xie, W., Pilot-Matias, T., Liossis, G., Larsen, L., Khatri, A., Podsadecki, T., Bernstein, B., Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N. Engl. J. Med. 370 (2014), 222–232.
143. Kumada, H., Hayashi, N., Izumi, N., Okanoue, T., Tsubouchi, H., Yatsuhashi, H., Kato, M., Rito, K., Komada, Y., Seto, C., Goto, S., Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: the CONCERTO-4 study. Hepatol. Res. 45 (2015), 501–513.
144. Kumada, H., Chayama, K., Rodrigues, L. Jr., Suzuki, F., Ikeda, K., Toyoda, H., Sato, K., Karino, Y., Matsuzaki, Y., Kioka, K., Setze, C., Pilot-Matias, T., Patwardhan, M., Vilchez, R.A., Burroughs, M., Redman, R., Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 62 (2015), 1037–1046.
145. Kumada, H., Suzuki, F., Suzuki, Y., Toyota, J., Karino, Y., Chayama, K., Kawakami, Y., Fujiyama, S., Ito, T., Itoh, Y., Tamura, E., Ueki, T., Ishikawa, H., Hu, W., McPhee, F., Linaberry, M., Hughes, E., Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. J. Gastroenterol. Hepatol. 31 (2016), 14–22.
146. Kuo, G., Choo, Q.L., Alter, H.J., Gitnick, G.L., Redeker, A.G., Purcell, R.H., Miyamura, T., Dienstag, J.L., Alter, M.J., Stevens, C.E., An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244 (1989), 362–364.
147. Kwo, P.Y., Lawitz, E.J., McCone, J., Schiff, E.R., Vierling, J.M., Pound, D., Davis, M.N., Galati, J.S., Gordon, S.C., Ravendhran, N., Rossaro, L., Anderson, F.H., Jacobson, I.M., Rubin, R., Koury, K., Pedicone, L.D., Brass, C.A., Chaudhri, E., Albrecht, J.K., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376 (2010), 705–716.
148. Kwo, P., Gitlin, N., Nahass, R., Bernstein, D., Etzkorn, K., Rojter, S., Schiff, E., Davis, M., Ruane, P., Younes, Z., Kalmeijer, R., Sinha, R., Peeters, M., Lenz, O., Fevery, B., De La Rosa, G., Scott, J., Witek, J., Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64 (2016), 370–380.
149. Kwo, P., Gane, E., Peng, C.Y., Pearlman, B., Vierling, J.M., Serfaty, L., Buti, M., Shafran, S., Stryszak, P., Lin, L., Gress, J., Black, S., Dutko, F.J., Robertson, M., Wahl, J., Lupinacci, L., Barr, E., Haber, B., Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152 (2017), 164–175.
150. Kwong, A.D., Kauffman, R.S., Hurter, P., Mueller, P., Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 29 (2011), 993–1003.
151. Lahser, F.C., Bystol, K., Curry, S., McMonagle, P., Xia, E., Ingravallo, P., Chase, R., Liu, R., Black, T., Hazuda, D., Howe, A.Y., Asante-Appiah, E., The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob. Agents Chemother. 60 (2016), 2954–2964.
152. Lalezari, J., Sullivan, J.G., Varunok, P., Galen, E., Kowdley, K.V., Rustgi, V., Aguilar, H., Felizarta, F., McGovern, B., King, M., Polepally, A.R., Cohen, D.E., Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J. Hepatol. 63 (2015), 364–369.
153. Lam, A.M., Espiritu, C., Bansal, S., Micolochick Steuer, H.M., Niu, C., Zennou, V., Keilman, M., Zhu, Y., Lan, S., Otto, M.J., Furman, P.A., Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56 (2012), 3359–3368.
154. LaPlante, S.R., Bos, M., Brochu, C., Chabot, C., Coulombe, R., Gillard, J.R., Jakalian, A., Poirier, M., Rancourt, J., Stammers, T., Thavonekham, B., Beaulieu, P.L., Kukolj, G., Tsantrizos, Y.S., Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). J. Med. Chem. 57 (2014), 1845–1854.
155. Lau, G., Benhamou, Y., Chen, G., Li, J., Shao, Q., Ji, D., Li, F., Li, B., Liu, J., Hou, J., Sun, J., Wang, C., Chen, J., Wu, V., Wong, A., Wong, C.L., Tsang, S.T., Wang, Y., Bassit, L., Tao, S., Jiang, Y., Hsiao, H.M., Ke, R., Perelson, A.S., Schinazi, R.F., Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet. Gastroenterol. Hepatol. 1 (2016), 97–104.
156. Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., Schultz, M., Davis, M.N., Kayali, Z., Reddy, K.R., Jacobson, I.M., Kowdley, K.V., Nyberg, L., Subramanian, G.M., Hyland, R.H., Arterburn, S., Jiang, D., McNally, J., Brainard, D., Symonds, W.T., McHutchison, J.G., Sheikh, A.M., Younossi, Z., Gane, E.J., Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368 (2013), 1878–1887.
157. Lawitz, E., Lalezari, J.P., Hassanein, T., Kowdley, K.V., Poordad, F.F., Sheikh, A.M., Afdhal, N.H., Bernstein, D.E., Dejesus, E., Freilich, B., Nelson, D.R., Dieterich, D.T., Jacobson, I.M., Jensen, D., Abrams, G.A., Darling, J.M., Rodriguez-Torres, M., Reddy, K.R., Sulkowski, M.S., Bzowej, N.H., Hyland, R.H., Mo, H., Lin, M., Mader, M., Hindes, R., Albanis, E., Symonds, W.T., Berrey, M.M., Muir, A., Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect. Dis. 13 (2013), 401–408.
158. Lawitz, E., Sulkowski, M.S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z.M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., Lim, J.K., Pockros, P.J., Scott, J.D., Fevery, B., Lambrecht, T., Ouwerkerk-Mahadevan, S., Callewaert, K., Symonds, W.T., Picchio, G., Lindsay, K.L., Beumont, M., Jacobson, I.M., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384 (2014), 1756–1765.
159. Lawitz, E., Poordad, F.F., Pang, P.S., Hyland, R.H., Ding, X., Mo, H., Symonds, W.T., McHutchison, J.G., Membreno, F.E., Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383 (2014), 515–523.
160. Lawitz, E., Jacobson, I.M., Nelson, D.R., Zeuzem, S., Sulkowski, M.S., Esteban, R., Brainard, D., McNally, J., Symonds, W.T., McHutchison, J.G., Dieterich, D., Gane, E., Development of sofosbuvir for the treatment of hepatitis C virus infection. Ann. N. Y. Acad. Sci. 1358 (2015), 56–67.
161. Lawitz, E., Poordad, F., Brainard, D.M., Hyland, R.H., An, D., Dvory-Sobol, H., Symonds, W.T., McHutchison, J.G., Membreno, F.E., Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 61 (2015), 769–775.
162. Lawitz, E., Makara, M., Akarca, U.S., Thuluvath, P.J., Preotescu, L.L., Varunok, P., Morillas, R.M., Hall, C., Mobashery, N., Redman, R., Pilot-Matias, T., Vilchez, R.A., Hezode, C., Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 149 (2015), 971–980 e971.
163. Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.P., Lester, L., Sievert, W., Ghalib, R., Balart, L., Sund, F., Lagging, M., Dutko, F., Shaughnessy, M., Hwang, P., Howe, A.Y., Wahl, J., Robertson, M., Barr, E., Haber, B., Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1075–1086.
164. Lawitz, E., Matusow, G., DeJesus, E., Yoshida, E.M., Felizarta, F., Ghalib, R., Godofsky, E., Herring, R.W., Poleynard, G., Sheikh, A., Tobias, H., Kugelmas, M., Kalmeijer, R., Peeters, M., Lenz, O., Fevery, B., De La Rosa, G., Scott, J., Sinha, R., Witek, J., Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64 (2016), 360–369.
165. Lawitz, E., Poordad, F., Gutierrez, J.A., Wells, J.T., Landaverde, C.E., Evans, B., Howe, A., Huang, H.C., Li, J.J., Hwang, P., Dutko, F.J., Robertson, M., Wahl, J., Barr, E., Haber, B., Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: a randomized trial. Hepatology 65 (2016), 439–450.
166. Lawitz, E., Reau, N., Hinestrosa, F., Rabinovitz, M., Schiff, E., Sheikh, A., Younes, Z., Herring, R. Jr., Reddy, K.R., Tran, T., Bennett, M., Nahass, R., Yang, J.C., Lu, S., Dvory-Sobol, H., Stamm, L.M., Brainard, D.M., McHutchison, J.G., Pearlman, B., Shiffman, M., Hawkins, T., Curry, M., Jacobson, I., Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial. Gastroenterology 151 (2016), 893–901.
167. Lawitz, E., Poordad, F., Hyland, R.H., Wang, J., Liu, L., Dvory-Sobol, H., Brainard, D.M., McHutchison, J.G., Gutierrez, J.A., Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies. Antivir. Ther. 21 (2016), 679–687.
168. Lazerwith, S.E., Lew, W., Zhang, J., Morganelli, P., Liu, Q., Canales, E., Clarke, M.O., Doerffler, E., Byun, D., Mertzman, M., Ye, H., Chong, L., Xu, L., Appleby, T., Chen, X., Fenaux, M., Hashash, A., Leavitt, S.A., Mabery, E., Matles, M., Mwangi, J.W., Tian, Y., Lee, Y.J., Zhang, J., Zhu, C., Murray, B.P., Watkins, W.J., Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection. J. Med. Chem. 57 (2014), 1893–1901.
169. Lee, Y.M., Duh, Y., Wang, S.T., Lai, M.M., Yuan, H.S., Lim, C., Using an old drug to target a new drug site: application of disulfiram to target the Zn-Site in HCV NS5A protein. J. Am. Chem. Soc. 138 (2016), 3856–3862.
170. Leroy, V., Angus, P., Bronowicki, J.P., Dore, G.J., Hezode, C., Pianko, S., Pol, S., Stuart, K., Tse, E., McPhee, F., Bhore, R., Jimenez-Exposito, M.J., Thompson, A.J., Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63 (2016), 1430–1441.
171. Li, G., De Clercq, E., HIV genome-wide protein associations: a review of 30 Years of research. Microbiol. Mol. Biol. Rev. 80 (2016), 679–731.
172. Lin, T.I., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., Vrang, L., de Kock, H., Wigerinck, P., Raboisson, P., Simmen, K., In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother. 53 (2009), 1377–1385.
173. Lin, L.T., Chung, C.Y., Hsu, W.C., Chang, S.P., Hung, T.C., Shields, J., Russell, R.S., Lin, C.C., Li, C.F., Yen, M.H., Tyrrell, D.L., Lin, C.C., Richardson, C.D., Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. J. Hepatol. 62 (2015), 541–548.
174. Lindenbach, B.D., Rice, C.M., Unravelling hepatitis C virus replication from genome to function. Nature 436 (2005), 933–938.
175. Link, J.O., Taylor, J.G., Xu, L., Mitchell, M., Guo, H., Liu, H., Kato, D., Kirschberg, T., Sun, J., Squires, N., Parrish, J., Keller, T., Yang, Z.Y., Yang, C., Matles, M., Wang, Y., Wang, K., Cheng, G., Tian, Y., Mogalian, E., Mondou, E., Cornpropst, M., Perry, J., Desai, M.C., Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57 (2014), 2033–2046.
176. Liu, Y., Lim, B.H., Jiang, W.W., Flentge, C.A., Hutchinson, D.K., Madigan, D.L., Randolph, J.T., Wagner, R., Maring, C.J., Kati, W.M., Molla, A., Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett. 22 (2012), 3747–3750.
177. Liverton, N.J., Holloway, M.K., McCauley, J.A., Rudd, M.T., Butcher, J.W., Carroll, S.S., DiMuzio, J., Fandozzi, C., Gilbert, K.F., Mao, S.S., McIntyre, C.J., Nguyen, K.T., Romano, J.J., Stahlhut, M., Wan, B.L., Olsen, D.B., Vacca, J.P., Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc. 130 (2008), 4607–4609.
178. Llovet, J.M., Villanueva, A., Liver cancer: effect of HCV clearance with direct-acting antiviral agents on HCC. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 561–562.
179. Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Habuka, N., Moomaw, E.W., Adachi, T., Hostomska, Z., The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87 (1996), 331–342.
180. Maasoumy, B., Vermehren, J., Welker, M.W., Bremer, B., Perner, D., Honer Zu Siederdissen, C., Deterding, K., Lehmann, P., Cloherty, G., Reinhardt, B., Pawlotsky, J.M., Manns, M.P., Zeuzem, S., Cornberg, M., Wedemeyer, H., Sarrazin, C., Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J. Hepatol. 65 (2016), 473–482.
181. Maheshwari, A., Ray, S., Thuluvath, P.J., Acute hepatitis C. Lancet 372 (2008), 321–332.
182. Manfroni, G., Cannalire, R., Barreca, M.L., Kaushik-Basu, N., Leyssen, P., Winquist, J., Iraci, N., Manvar, D., Paeshuyse, J., Guhamazumder, R., Basu, A., Sabatini, S., Tabarrini, O., Danielson, U.H., Neyts, J., Cecchetti, V., The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors. J. Med. Chem. 57 (2014), 1952–1963.
183. Manfroni, G., Manvar, D., Barreca, M.L., Kaushik-Basu, N., Leyssen, P., Paeshuyse, J., Cannalire, R., Iraci, N., Basu, A., Chudaev, M., Zamperini, C., Dreassi, E., Sabatini, S., Tabarrini, O., Neyts, J., Cecchetti, V., New pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors. J. Med. Chem. 57 (2014), 3247–3262.
184. Mangia, A., Arleo, A., Copetti, M., Miscio, M., Piazzolla, V., Santoro, R., Squillante, M.M., The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int. 36 (2016), 971–976.
185. Manns, M.P., Wedemeyer, H., Cornberg, M., Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006), 1350–1359.
186. Manns, M., Marcellin, P., Poordad, F., de Araujo, E.S., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Sinha, R., Beumont-Mauviel, M., Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384 (2014), 414–426.
187. Manns, M., Samuel, D., Gane, E.J., Mutimer, D., McCaughan, G., Buti, M., Prieto, M., Calleja, J.L., Peck-Radosavljevic, M., Mullhaupt, B., Agarwal, K., Angus, P., Yoshida, E.M., Colombo, M., Rizzetto, M., Dvory-Sobol, H., Denning, J., Arterburn, S., Pang, P.S., Brainard, D., McHutchison, J.G., Dufour, J.F., Van Vlierberghe, H., van Hoek, B., Forns, X., SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect. Dis. 16 (2016), 685–697.
188. Marcellin, P., Cooper, C., Balart, L., Larrey, D., Box, T., Yoshida, E., Lawitz, E., Buggisch, P., Ferenci, P., Weltman, M., Labriola-Tompkins, E., Le Pogam, S., Najera, I., Thomas, D., Hooper, G., Shulman, N.S., Zhang, Y., Navarro, M.T., Lim, C.Y., Brunda, M., Terrault, N.A., Yetzer, E.S., Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Gastroenterology 145 (2013), 790–800 e793.
189. McCauley, J.A., Rudd, M.T., Hepatitis C virus NS3/4a protease inhibitors. Curr. Opin. Pharmacol. 30 (2016), 84–92.
190. McGivern, D.R., Masaki, T., Williford, S., Ingravallo, P., Feng, Z., Lahser, F., Asante-Appiah, E., Neddermann, P., De Francesco, R., Howe, A.Y., Lemon, S.M., Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147 (2014), 453–462 e457.
191. Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., Barnes, E., Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
192. Mizokami, M., Yokosuka, O., Takehara, T., Sakamoto, N., Korenaga, M., Mochizuki, H., Nakane, K., Enomoto, H., Ikeda, F., Yanase, M., Toyoda, H., Genda, T., Umemura, T., Yatsuhashi, H., Ide, T., Toda, N., Nirei, K., Ueno, Y., Nishigaki, Y., Betular, J., Gao, B., Ishizaki, A., Omote, M., Mo, H., Garrison, K., Pang, P.S., Knox, S.J., Symonds, W.T., McHutchison, J.G., Izumi, N., Omata, M., Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis. 15 (2015), 645–653.
193. Moradpour, D., Penin, F., Hepatitis C virus proteins: from structure to function. Curr. Top. Microbiol. Immunol. 369 (2013), 113–142.
194. Moradpour, D., Penin, F., Rice, C.M., Replication of hepatitis C virus. Nat. Rev. Microbiol. 5 (2007), 453–463.
195. Morales, J.M., Fabrizi, F., Hepatitis C and its impact on renal transplantation. Nat. Rev. Nephrol. 11 (2015), 172–182.
196. Moreno, C., Hezode, C., Marcellin, P., Bourgeois, S., Francque, S., Samuel, D., Zoulim, F., Grange, J.D., Shukla, U., Lenz, O., Ouwerkerk-Mahadevan, S., Fevery, B., Peeters, M., Beumont, M., Jessner, W., Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J. Hepatol. 62 (2015), 1047–1055.
197. Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1459–1544.
198. Moucari, R., Forestier, N., Larrey, D., Guyader, D., Couzigou, P., Benhamou, Y., Voitot, H., Vidaud, M., Seiwert, S., Bradford, B., Zeuzem, S., Marcellin, P., Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 59 (2010), 1694–1698.
199. Muir, A.J., Poordad, F., Lalezari, J., Everson, G., Dore, G.J., Herring, R., Sheikh, A., Kwo, P., Hezode, C., Pockros, P.J., Tran, A., Yozviak, J., Reau, N., Ramji, A., Stuart, K., Thompson, A.J., Vierling, J., Freilich, B., Cooper, J., Ghesquiere, W., Yang, R., McPhee, F., Hughes, E.A., Swenson, E.S., Yin, P.D., Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 313 (2015), 1736–1744.
200. Murphy, D.G., Sablon, E., Chamberland, J., Fournier, E., Dandavino, R., Tremblay, C.L., Hepatitis C virus genotype 7, a new genotype originating from central Africa. J. Clin. Microbiol. 53 (2015), 967–972.
201. Nahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., Guyader, D., Fontaine, H., Larrey, D., De Ledinghen, V., Ouzan, D., Zoulim, F., Roulot, D., Tran, A., Bronowicki, J.P., Zarski, J.P., Leroy, V., Riachi, G., Cales, P., Peron, J.M., Alric, L., Bourliere, M., Mathurin, P., Dharancy, S., Blanc, J.F., Abergel, A., Serfaty, L., Mallat, A., Grange, J.D., Attali, P., Bacq, Y., Wartelle, C., Dao, T., Benhamou, Y., Pilette, C., Silvain, C., Christidis, C., Capron, D., Bernard-Chabert, B., Zucman, D., Di Martino, V., Thibaut, V., Salmon, D., Ziol, M., Sutton, A., Pol, S., Roudot-Thoraval, F., Group, A.C.C., Eradication of Hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152 (2017), 142–156 e142.
202. Neelamkavil, S.F., Agrawal, S., Bara, T., Bennett, C., Bhat, S., Biswas, D., Brockunier, L., Buist, N., Burnette, D., Cartwright, M., Chackalamannil, S., Chase, R., Chelliah, M., Chen, A., Clasby, M., Colandrea, V.J., Davies, I.W., Eagen, K., Guo, Z., Han, Y., Howe, J., Jayne, C., Josien, H., Kargman, S., Marcantonio, K., Miao, S., Miller, R., Nolting, A., Pinto, P., Rajagopalan, M., Ruck, R.T., Shah, U., Soriano, A., Sperbeck, D., Velazquez, F., Wu, J., Xia, Y., Venkatraman, S., Discovery of MK-8831, a novel spiro-proline macrocycle as a Pan-Genotypic HCV-NS3/4a protease inhibitor. ACS Med. Chem. Lett. 7 (2016), 111–116.
203. Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N., Freilich, B.F., Younes, Z.H., Harlan, W., Ghalib, R., Oguchi, G., Thuluvath, P.J., Ortiz-Lasanta, G., Rabinovitz, M., Bernstein, D., Bennett, M., Hawkins, T., Ravendhran, N., Sheikh, A.M., Varunok, P., Kowdley, K.V., Hennicken, D., McPhee, F., Rana, K., Hughes, E.A., ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
204. Nettles, J.H., Stanton, R.A., Broyde, J., Amblard, F., Zhang, H., Zhou, L., Shi, J., McBrayer, T.R., Whitaker, T., Coats, S.J., Kohler, J.J., Schinazi, R.F., Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. J. Med. Chem. 57 (2014), 10031–10043.
205. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., Perelson, A.S., Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998), 103–107.
206. Njoroge, F.G., Chen, K.X., Shih, N.Y., Piwinski, J.J., Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc. Chem. Res. 41 (2008), 50–59.
207. Ogata, N., Alter, H.J., Miller, R.H., Purcell, R.H., Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 3392–3396.
208. Ogawa, E., Furusyo, N., Nomura, H., Takahashi, K., Higashi, N., Kawano, A., Dohmen, K., Satoh, T., Azuma, K., Nakamuta, M., Koyanagi, T., Kato, M., Shimoda, S., Kajiwara, E., Hayashi, J., Kyushu University Liver Disease Study (KULDS) Group. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antivir. Res. 136 (2016), 37–44.
209. O'Leary, J.G., Fontana, R.J., Brown, K., Burton, J.R. Jr., Firpi-Morell, R., Muir, A., O'Brien, C., Rabinovitz, M., Reddy, R., Ryan, R., Shprecher, A., Villadiego, S., Prabhakar, A., Brown, R.S. Jr., Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl. Int. Off. J. European Soc. Organ Transpl. 30 (2017), 196–208.
210. Omata, M., Nishiguchi, S., Ueno, Y., Mochizuki, H., Izumi, N., Ikeda, F., Toyoda, H., Yokosuka, O., Nirei, K., Genda, T., Umemura, T., Takehara, T., Sakamoto, N., Nishigaki, Y., Nakane, K., Toda, N., Ide, T., Yanase, M., Hino, K., Gao, B., Garrison, K.L., Dvory-Sobol, H., Ishizaki, A., Omote, M., Brainard, D., Knox, S., Symonds, W.T., McHutchison, J.G., Yatsuhashi, H., Mizokami, M., Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J. Viral Hepat. 21 (2014), 762–768.
211. Osinusi, A., Meissner, E.G., Lee, Y.J., Bon, D., Heytens, L., Nelson, A., Sneller, M., Kohli, A., Barrett, L., Proschan, M., Herrmann, E., Shivakumar, B., Gu, W., Kwan, R., Teferi, G., Talwani, R., Silk, R., Kotb, C., Wroblewski, S., Fishbein, D., Dewar, R., Highbarger, H., Zhang, X., Kleiner, D., Wood, B.J., Chavez, J., Symonds, W.T., Subramanian, M., McHutchison, J., Polis, M.A., Fauci, A.S., Masur, H., Kottilil, S., Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 310 (2013), 804–811.
212. Osinusi, A., Kohli, A., Marti, M.M., Nelson, A., Zhang, X., Meissner, E.G., Silk, R., Townsend, K., Pang, P.S., Subramanian, G.M., McHutchison, J.G., Fauci, A.S., Masur, H., Kottilil, S., Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann. Intern Med. 161 (2014), 634–638.
213. OuYang, B., Xie, S., Berardi, M.J., Zhao, X., Dev, J., Yu, W., Sun, B., Chou, J.J., Unusual architecture of the p7 channel from hepatitis C virus. Nature 498 (2013), 521–525.
214. Owens, C.M., Brasher, B.B., Polemeropoulos, A., Rhodin, M.H., McAllister, N., Peng, X., Wang, C., Ying, L., Cao, H., Lawitz, E., Poordad, F., Rondon, J., Box, T.D., Zeuzem, S., Buggisch, P., Lin, K., Qiu, Y.L., Jiang, L., Colvin, R., Or, Y.S., Preclinical profile and clinical efficacy of a novel hepatitis C virus NS5A inhibitor, EDP-239. Antimicrob. Agents Chemother. 60 (2016), 6207–6215.
215. Owens, C.M., Brasher, B.B., Polemeropoulos, A., Rhodin, M.H., McAllister, N., Wong, K.A., Jones, C.T., Jiang, L., Lin, K., Or, Y.S., Preclinical and clinical resistance profile of EDP-239, a novel hepatitis C virus NS5A inhibitor. Antimicrob. Agents Chemother. 60 (2016), 6216–6226.
216. Pawlotsky, J.M., Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151 (2016), 70–86.
217. Pawlotsky, J.M., Flisiak, R., Sarin, S.K., Rasenack, J., Piratvisuth, T., Chuang, W.L., Peng, C.Y., Foster, G.R., Shah, S., Wedemeyer, H., Hezode, C., Zhang, W., Wong, K.A., Li, B., Avila, C., Naoumov, N.V., VITAL-1 study team. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology 62 (2015), 1013–1023.
218. Perin, P.M., Haid, S., Brown, R.J., Doerrbecker, J., Schulze, K., Zeilinger, C., von Schaewen, M., Heller, B., Vercauteren, K., Luxenburger, E., Baktash, Y.M., Vondran, F.W., Speerstra, S., Awadh, A., Mukhtarov, F., Schang, L.M., Kirschning, A., Muller, R., Guzman, C.A., Kaderali, L., Randall, G., Meuleman, P., Ploss, A., Pietschmann, T., Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology 63 (2016), 49–62.
219. Phillips, B., Cai, R., Delaney, W., Du, Z., Ji, M., Jin, H., Lee, J., Li, J., Niedziela-Majka, A., Mish, M., Pyun, H.J., Saugier, J., Tirunagari, N., Wang, J., Yang, H., Wu, Q., Sheng, C., Zonte, C., Highly potent HCV NS4B inhibitors with activity against multiple genotypes. J. Med. Chem. 57 (2014), 2161–2166.
220. Pianko, S., Flamm, S.L., Shiffman, M.L., Kumar, S., Strasser, S.I., Dore, G.J., McNally, J., Brainard, D.M., Han, L., Doehle, B., Mogalian, E., McHutchison, J.G., Rabinovitz, M., Towner, W.J., Gane, E.J., Stedman, C.A., Reddy, K.R., Roberts, S.K., Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann. Intern Med. 163 (2015), 809–817.
221. Pilot-Matias, T., Tripathi, R., Cohen, D., Gaultier, I., Dekhtyar, T., Lu, L., Reisch, T., Irvin, M., Hopkins, T., Pithawalla, R., Middleton, T., Ng, T., McDaniel, K., Or, Y.S., Menon, R., Kempf, D., Molla, A., Collins, C., In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob. Agents Chemother. 59 (2015), 988–997.
222. Pockros, P.J., Jensen, D., Tsai, N., Taylor, R., Ramji, A., Cooper, C., Dickson, R., Tice, A., Kulkarni, R., Vierling, J.M., Lou Munson, M., Chen, Y.C., Najera, I., Thommes, J., JUMP-C Investigators. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 58 (2013), 514–523.
223. Pockros, P.J., Reddy, K.R., Mantry, P.S., Cohen, E., Bennett, M., Sulkowski, M.S., Bernstein, D.E., Cohen, D.E., Shulman, N.S., Wang, D., Khatri, A., Abunimeh, M., Podsadecki, T., Lawitz, E., Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150 (2016), 1590–1598.
224. Pol, S., Sulkowski, M.S., Hassanein, T., Gane, E.J., Liu, L., Mo, H., Doehle, B., Kanwar, B., Brainard, D., Subramanian, G.M., Symonds, W.T., McHutchison, J.G., Nahass, R.G., Bennett, M., Jacobson, I.M., Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology 62 (2015), 129–134.
225. Pol, S., Bourliere, M., Lucier, S., Hezode, C., Dorival, C., Larrey, D., Bronowicki, J.P., Ledinghen, V.D., Zoulim, F., Tran, A., Metivier, S., Zarski, J.P., Samuel, D., Guyader, D., Marcellin, P., Minello, A., Alric, L., Thabut, D., Chazouilleres, O., Riachi, G., Bourcier, V., Mathurin, P., Loustaud-Ratti, V., D'Alteroche, L., Fouchard-Hubert, I., Habersetzer, F., Causse, X., Geist, C., Rosa, I., Gournay, J., Saillard, E., Billaud, E., Petrov-Sanchez, V., Diallo, A., Fontaine, H., Carrat, F., ANRS/AFEF HEPATHER study group. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J. Hepatol. 66 (2017), 39–47.
226. Poordad, F., McCone, J. Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., Jacobson, I.M., Reddy, K.R., Goodman, Z.D., Boparai, N., DiNubile, M.J., Sniukiene, V., Brass, C.A., Albrecht, J.K., Bronowicki, J.P., SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364 (2011), 1195–1206.
227. Poordad, F., Lawitz, E., Reddy, K.R., Afdhal, N.H., Hezode, C., Zeuzem, S., Lee, S.S., Calleja, J.L., Brown, R.S. Jr., Craxi, A., Wedemeyer, H., Nyberg, L., Nelson, D.R., Rossaro, L., Balart, L., Morgan, T.R., Bacon, B.R., Flamm, S.L., Kowdley, K.V., Deng, W., Koury, K.J., Pedicone, L.D., Dutko, F.J., Burroughs, M.H., Alves, K., Wahl, J., Brass, C.A., Albrecht, J.K., Sulkowski, M.S., Protocol 6086 Investigators. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection–a randomized trial. Gastroenterology 145 (2013), 1035–1044 e1035.
228. Poordad, F., Hezode, C., Trinh, R., Kowdley, K.V., Zeuzem, S., Agarwal, K., Shiffman, M.L., Wedemeyer, H., Berg, T., Yoshida, E.M., Forns, X., Lovell, S.S., Da Silva-Tillmann, B., Collins, C.A., Campbell, A.L., Podsadecki, T., Bernstein, B., ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370 (2014), 1973–1982.
229. Poordad, F., Sievert, W., Mollison, L., Bennett, M., Tse, E., Brau, N., Levin, J., Sepe, T., Lee, S.S., Angus, P., Conway, B., Pol, S., Boyer, N., Bronowicki, J.P., Jacobson, I., Muir, A.J., Reddy, K.R., Tam, E., Ortiz-Lasanta, G., de Ledinghen, V., Sulkowski, M., Boparai, N., McPhee, F., Hughes, E., Swenson, E.S., Yin, P.D., Unity-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 313 (2015), 1728–1735.
230. Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., McPhee, F., Hughes, E.A., Noviello, S., Swenson, E.S., Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
231. Poordad, F., Gordon, S.C., Asatryan, A., Felizarta, F., Reindollar, R.W., Landis, C., Fried, M.W., Bernstein, D.E., Ng, T.I., Lin, C.-W., Liu, R., Kort, J., Mensa, F.J., High efficacy of ABT-493 and ABT-530 in HCV genotype 1-infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I study. 51st Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 15 April 2016.
232. Poordad, F., Landis, C.S., Asatryan, A., Jackson, D.F. 3rd, Ng, T.I., Fu, B., Lin, C.W., Yao, B., Kort, J., High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int. 36 (2016), 1125–1132.
233. Prigozhin, D.M., Modis, Y., Flunarizine arrests hepatitis C virus membrane fusion. Hepatology 63 (2016), 14–16.
234. Qian, X.J., Zhu, Y.Z., Zhao, P., Qi, Z.T., Entry inhibitors: new advances in HCV treatment. Emerg. Microb. Infect., 5, 2016, e3.
235. Ramirez, S., Mikkelsen, L.S., Gottwein, J.M., Bukh, J., Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir. Gastroenterology 151 (2016), 973–985 e972.
236. Reddy, K.R., Zeuzem, S., Zoulim, F., Weiland, O., Horban, A., Stanciu, C., Villamil, F.G., Andreone, P., George, J., Dammers, E., Fu, M., Kurland, D., Lenz, O., Ouwerkerk-Mahadevan, S., Verbinnen, T., Scott, J., Jessner, W., Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect. Dis. 15 (2015), 27–35.
237. Reddy, K.R., Bourliere, M., Sulkowski, M., Omata, M., Zeuzem, S., Feld, J.J., Lawitz, E., Marcellin, P., Welzel, T.M., Hyland, R., Ding, X., Yang, J., Knox, S., Pang, P., Dvory-Sobol, H., Subramanian, G.M., Symonds, W., McHutchison, J.G., Mangia, A., Gane, E., Mizokami, M., Pol, S., Afdhal, N., Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
238. Rehermann, B., Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Investig. 119 (2009), 1745–1754.
239. Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., Diaz, A., Vilana, R., Darnell, A., Varela, M., Sangro, B., Calleja, J.L., Forns, X., Bruix, J., Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 65 (2016), 719–726.
240. Rodriguez-Torres, M., Glass, S., Hill, J., Freilich, B., Hassman, D., Di Bisceglie, A.M., Taylor, J.G., Kirby, B.J., Dvory-Sobol, H., Yang, J.C., An, D., Stamm, L.M., Brainard, D.M., Kim, S., Krefetz, D., Smith, W., Marbury, T., Lawitz, E., GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J. Viral Hepat. 23 (2016), 614–622.
241. Rosenquist, A., Samuelsson, B., Johansson, P.O., Cummings, M.D., Lenz, O., Raboisson, P., Simmen, K., Vendeville, S., de Kock, H., Nilsson, M., Horvath, A., Kalmeijer, R., de la Rosa, G., Beumont-Mauviel, M., Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem. 57 (2014), 1673–1693.
242. Roth, D., Nelson, D.R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H. Jr., Martin, P., Pol, S., Londono, M.C., Hassanein, T., Zamor, P.J., Zuckerman, E., Wan, S., Jackson, B., Nguyen, B.Y., Robertson, M., Barr, E., Wahl, J., Greaves, W., Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
243. Ruane, P.J., Ain, D., Stryker, R., Meshrekey, R., Soliman, M., Wolfe, P.R., Riad, J., Mikhail, S., Kersey, K., Jiang, D., Massetto, B., Doehle, B., Kirby, B.J., Knox, S.J., McHutchison, J.G., Symonds, W.T., Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J. Hepatol. 62 (2015), 1040–1046.
244. Sarrazin, C., The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. 64 (2016), 486–504.
245. Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., Doehle, B.P., Pang, P.S., Chuang, S.M., Ma, J., Ding, X., Afdhal, N.H., Kowdley, K.V., Gane, E.J., Lawitz, E., Brainard, D.M., McHutchison, J.G., Miller, M.D., Mo, H., Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 151 (2016), 501–512 e501.
246. Scheel, T.K., Rice, C.M., Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19 (2013), 837–849.
247. Schreiber, J., McNally, J., Chodavarapu, K., Svarovskaia, E., Moreno, C., Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology 64 (2016), 983–985.
248. Scola, P.M., Wang, A.X., Good, A.C., Sun, L.Q., Combrink, K.D., Campbell, J.A., Chen, J., Tu, Y., Sin, N., Venables, B.L., Sit, S.Y., Chen, Y., Cocuzza, A., Bilder, D.M., D'Andrea, S., Zheng, B., Hewawasam, P., Ding, M., Thuring, J., Li, J., Hernandez, D., Yu, F., Falk, P., Zhai, G., Sheaffer, A.K., Chen, C., Lee, M.S., Barry, D., Knipe, J.O., Li, W., Han, Y.H., Jenkins, S., Gesenberg, C., Gao, Q., Sinz, M.W., Santone, K.S., Zvyaga, T., Rajamani, R., Klei, H.E., Colonno, R.J., Grasela, D.M., Hughes, E., Chien, C., Adams, S., Levesque, P.C., Li, D., Zhu, J., Meanwell, N.A., McPhee, F., Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57 (2014), 1708–1729.
249. Scola, P.M., Sun, L.Q., Wang, A.X., Chen, J., Sin, N., Venables, B.L., Sit, S.Y., Chen, Y., Cocuzza, A., Bilder, D.M., D'Andrea, S.V., Zheng, B., Hewawasam, P., Tu, Y., Friborg, J., Falk, P., Hernandez, D., Levine, S., Chen, C., Yu, F., Sheaffer, A.K., Zhai, G., Barry, D., Knipe, J.O., Han, Y.H., Schartman, R., Donoso, M., Mosure, K., Sinz, M.W., Zvyaga, T., Good, A.C., Rajamani, R., Kish, K., Tredup, J., Klei, H.E., Gao, Q., Mueller, L., Colonno, R.J., Grasela, D.M., Adams, S.P., Loy, J., Levesque, P.C., Sun, H., Shi, H., Sun, L., Warner, W., Li, D., Zhu, J., Meanwell, N.A., McPhee, F., The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57 (2014), 1730–1752.
250. Scull, M.A., Schneider, W.M., Flatley, B.R., Hayden, R., Fung, C., Jones, C.T., van de Belt, M., Penin, F., Rice, C.M., The N-terminal helical region of the hepatitis C virus p7 Ion Channel protein is critical for infectious virus production. PLoS Pathog., 11, 2015, e1005297.
251. Selzner, N., Guindi, M., Renner, E.L., Berenguer, M., Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J. Hepatol. 55 (2011), 207–217.
252. Sheng, X.C., Casarez, A., Cai, R., Clarke, M.O., Chen, X., Cho, A., Delaney, WEt, Doerffler, E., Ji, M., Mertzman, M., Pakdaman, R., Pyun, H.J., Rowe, T., Wu, Q., Xu, J., Kim, C.U., Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg. Med. Chem. Lett. 22 (2012), 1394–1396.
253. Sheng, X.C., Appleby, T., Butler, T., Cai, R., Chen, X., Cho, A., Clarke, M.O., Cottell, J., Delaney, W.E. IV, Doerffler, E., Link, J., Ji, M., Pakdaman, R., Pyun, H.J., Wu, Q., Xu, J., Kim, C.U., Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg. Med. Chem. Lett. 22 (2012), 2629–2634.
254. Shepard, C.W., Finelli, L., Alter, M.J., Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005), 558–567.
255. Shiffman, M.L., James, A.M., Long, A.G., Alexander, P.C., Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am. J. Gastroenterol. 110 (2015), 1179–1185.
256. Shih, I.H., Vliegen, I., Peng, B., Yang, H., Hebner, C., Paeshuyse, J., Purstinger, G., Fenaux, M., Tian, Y., Mabery, E., Qi, X., Bahador, G., Paulson, M., Lehman, L.S., Bondy, S., Tse, W., Reiser, H., Lee, W.A., Schmitz, U., Neyts, J., Zhong, W., Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55 (2011), 4196–4203.
257. Shimura, S., Ishima, M., Nakajima, S., Fujii, T., Himeno, N., Ikeda, K., Izaguirre-Carbonell, J., Murata, H., Takeuchi, T., Kamisuki, S., Suzuki, T., Kuramochi, K., Watashi, K., Kobayashi, S., Sugawara, F., Total synthesis and anti-hepatitis C virus activity of MA026. J. Am. Chem. Soc. 135 (2013), 18949–18956.
258. Silva, M.O., Treitel, M., Graham, D.J., Curry, S., Frontera, M.J., McMonagle, P., Gupta, S., Hughes, E., Chase, R., Lahser, F., Barnard, R.J., Howe, A.Y., Howe, J.A., Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J. Hepatol. 59 (2013), 31–37.
259. Simmonds, P., The origin of hepatitis C virus. Curr. Top. Microbiol. Immunol. 369 (2013), 1–15.
260. Sofia, M.J., Bao, D., Chang, W., Du, J., Nagarathnam, D., Rachakonda, S., Reddy, P.G., Ross, B.S., Wang, P., Zhang, H.R., Bansal, S., Espiritu, C., Keilman, M., Lam, A.M., Steuer, H.M., Niu, C., Otto, M.J., Furman, P.A., Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53 (2010), 7202–7218.
261. Soumana, D.I., Kurt Yilmaz, N., Ali, A., Prachanronarong, K.L., Schiffer, C.A., Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. J. Am. Chem. Soc. 138 (2016), 11850–11859.
262. Sperl, J., Horvath, G., Halota, W., Ruiz-Tapiador, J.A., Streinu-Cercel, A., Jancoriene, L., Werling, K., Kileng, H., Koklu, S., Gerstoft, J., Urbanek, P., Flisiak, R., Leiva, R., Kazenaite, E., Prinzing, R., Patel, S., Qiu, J., Asante-Appiah, E., Wahl, J., Nguyen, B.Y., Barr, E., Platt, H.L., Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J. Hepatol. 65 (2016), 1112–1119.
263. Sterling, R.K., Kuo, A., Rustgi, V.K., Sulkowski, M.S., Stewart, T.G., Fenkel, J.M., El-Genaidi, H., Mah'moud, M.A., Abraham, G.M., Stewart, P.W., Akushevich, L., Nelson, D.R., Fried, M.W., Di Bisceglie, A.M., Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment. Pharmacol. Ther. 41 (2015), 671–685.
264. Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A.S., Hinestrosa, F., Thuluvath, P.J., Schwartz, H., Nelson, D.R., Everson, G.T., Eley, T., Wind-Rotolo, M., Huang, S.P., Gao, M., Hernandez, D., McPhee, F., Sherman, D., Hindes, R., Symonds, W., Pasquinelli, C., Grasela, D.M., AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370 (2014), 211–221.
265. Sulkowski, M.S., Kang, M., Matining, R., Wyles, D., Johnson, V.A., Morse, G.D., Amorosa, V., Bhattacharya, D., Coughlin, K., Wong-Staal, F., Glesby, M.J., AIDS Clinical Trials Group A5277 Protocol Team. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J. Infect. Dis. 209 (2014), 658–667.
266. Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J.M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., Shibolet, O., Serfaty, L., Bourliere, M., DeJesus, E., Zuckerman, E., Dutko, F., Shaughnessy, M., Hwang, P., Howe, A.Y., Wahl, J., Robertson, M., Barr, E., Haber, B., Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1087–1097.
267. Sulkowski, M.S., Vargas, H.E., Di Bisceglie, A.M., Kuo, A., Reddy, K.R., Lim, J.K., Morelli, G., Darling, J.M., Feld, J.J., Brown, R.S., Frazier, L.M., Stewart, T.G., Fried, M.W., Nelson, D.R., Jacobson, I.M., HCV-TARGET Study Group. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150 (2016), 419–429.
268. Sun, J.H., O'Boyle, D.R. 2nd, Fridell, R.A., Langley, D.R., Wang, C., Roberts, S.B., Nower, P., Johnson, B.M., Moulin, F., Nophsker, M.J., Wang, Y.K., Liu, M., Rigat, K., Tu, Y., Hewawasam, P., Kadow, J., Meanwell, N.A., Cockett, M., Lemm, J.A., Kramer, M., Belema, M., Gao, M., Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A. Nature 527 (2015), 245–248.
269. Sun, L.Q., Mull, E., Zheng, B., D'Andrea, S., Zhao, Q., Wang, A.X., Sin, N., Venables, B.L., Sit, S.Y., Chen, Y., Chen, J., Cocuzza, A., Bilder, D.M., Mathur, A., Rampulla, R., Chen, B.C., Palani, T., Ganesan, S., Arunachalam, P.N., Falk, P., Levine, S., Chen, C., Friborg, J., Yu, F., Hernandez, D., Sheaffer, A.K., Knipe, J.O., Han, Y.H., Schartman, R., Donoso, M., Mosure, K., Sinz, M.W., Zvyaga, T., Rajamani, R., Kish, K., Tredup, J., Klei, H.E., Gao, Q., Ng, A., Mueller, L., Grasela, D.M., Adams, S., Loy, J., Levesque, P.C., Sun, H., Shi, H., Sun, L., Warner, W., Li, D., Zhu, J., et al. Discovery of a potent acyclic, tripeptidic, acyl sulfonamide inhibitor of hepatitis C virus NS3 protease as a back-up to asunaprevir with the potential for once-daily dosing. J. Med. Chem. 59 (2016), 8042–8060.
270. Syder, A.J., Lee, H., Zeisel, M.B., Grove, J., Soulier, E., Macdonald, J., Chow, S., Chang, J., Baumert, T.F., McKeating, J.A., McKelvy, J., Wong-Staal, F., Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol. 54 (2011), 48–55.
271. Terrault, N.A., Zeuzem, S., Di Bisceglie, A.M., Lim, J.K., Pockros, P.J., Frazier, L.M., Kuo, A., Lok, A.S., Shiffman, M.L., Ben Ari, Z., Akushevich, L., Vainorius, M., Sulkowski, M.S., Fried, M.W., Nelson, D.R., HCV-TARGET Study Group. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated of sustained virologic response. Gastroenterology 151 (2016), 1131–1140.
272. The ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J. Hepatol. 65 (2016), 734–740.
273. Thrift, A.P., El-Serag, H.B., Kanwal, F., Global epidemiology and burden of HCV infection and HCV-related disease. Nat. Rev. Gastroenterol. Hepatol. 14 (2017), 122–132.
274. Tong, X., Le Pogam, S., Li, L., Haines, K., Piso, K., Baronas, V., Yan, J.M., So, S.S., Klumpp, K., Najera, I., In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J. Infect. Dis. 209 (2014), 668–675.
275. Toyota, J., Karino, Y., Suzuki, F., Ikeda, F., Ido, A., Tanaka, K., Takaguchi, K., Naganuma, A., Tomita, E., Chayama, K., Fujiyama, S., Inada, Y., Yoshiji, H., Watanabe, H., Ishikawa, H., Hu, W., McPhee, F., Linaberry, M., Yin, P.D., Swenson, E.S., Kumada, H., Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J. Gastroenterol. 52 (2016), 385–395.
276. Vausselin, T., Seron, K., Lavie, M., Mesalam, A.A., Lemasson, M., Belouzard, S., Feneant, L., Danneels, A., Rouille, Y., Cocquerel, L., Foquet, L., Rosenberg, A.R., Wychowski, C., Meuleman, P., Melnyk, P., Dubuisson, J., Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus. J. Virol. 90 (2016), 8422–8434.
277. Vierling, J.M., Davis, M., Flamm, S., Gordon, S.C., Lawitz, E., Yoshida, E.M., Galati, J., Luketic, V., McCone, J., Jacobson, I., Marcellin, P., Muir, A.J., Poordad, F., Pedicone, L.D., Albrecht, J., Brass, C., Howe, A.Y., Colvard, L.Y., Helmond, F.A., Deng, W., Treitel, M., Wahl, J., Bronowicki, J.P., Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J. Hepatol. 60 (2014), 748–756.
278. Vince, B., Hill, J.M., Lawitz, E.J., O'Riordan, W., Webster, L.R., Gruener, D.M., Mofsen, R.S., Murillo, A., Donovan, E., Chen, J., McCarville, J.F., Sullivan-Bolyai, J.Z., Mayers, D., Zhou, X.J., A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. J. Hepatol. 60 (2014), 920–927.
279. Wagner, F., Thompson, R., Kantaridis, C., Simpson, P., Troke, P.J., Jagannatha, S., Neelakantan, S., Purohit, V.S., Hammond, J.L., Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 54 (2011), 50–59.
280. Walker, J., Crosby, R., Wang, A., Woldu, E., Vamathevan, J., Voitenleitner, C., You, S., Remlinger, K., Duan, M., Kazmierski, W., Hamatake, R., Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob. Agents Chemother. 58 (2014), 38–47.
281. Wang, N.Y., Xu, Y., Zuo, W.Q., Xiao, K.J., Liu, L., Zeng, X.X., You, X.Y., Zhang, L.D., Gao, C., Liu, Z.H., Ye, T.H., Xia, Y., Xiong, Y., Song, X.J., Lei, Q., Peng, C.T., Tang, H., Yang, S.Y., Wei, Y.Q., Yu, L.T., Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. J. Med. Chem. 58 (2015), 2764–2778.
282. Wang, H., Cui, W., Guo, C., Chen, B.Z., Ji, M., Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055. Biochem. Cell Biol. 94 (2016), 147–158.
283. Webster, D.P., Klenerman, P., Collier, J., Jeffery, K.J., Development of novel treatments for hepatitis C. Lancet Infect. Dis. 9 (2009), 108–117.
284. Wedemeyer, H., Jensen, D., Herring, R. Jr., Ferenci, P., Ma, M.M., Zeuzem, S., Rodriguez-Torres, M., Bzowej, N., Pockros, P., Vierling, J., Ipe, D., Munson, M.L., Chen, Y.C., Najera, I., Thommes, J., PROPEL Investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 58 (2013), 524–537.
285. Wei, L., Han, T., Yang, D., Heo, J., Shang, J., Cheng, J., Chen, X., Xie, Q., Kim, J.H., Kalmeijer, R., Ouwerkerk-Mahadevan, S., Hoeben, E., Lenz, O., Verbinnen, T., Sinha, R., Li, M., Scott, J., Peeters, M., Witek, J., Tiger team. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naive patients in China and South Korea. J. Gastroenterol. Hepatol. 31 (2016), 912–920.
286. Welzel, T.M., Dultz, G., Zeuzem, S., Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J. Hepatol. 61 (2014), S98–S107.
287. Welzel, T.M., Nelson, D.R., Morelli, G., Di Bisceglie, A., Reddy, R.K., Kuo, A., Lim, J.K., Darling, J., Pockros, P., Galati, J.S., Frazier, L.M., Alqahtani, S., Sulkowski, M.S., Vainorius, M., Akushevich, L., Fried, M.W., Zeuzem, S., HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut, 2016, 10.1136/gutjnl-2016–311609.
288. Welzel, T.M., Petersen, J., Herzer, K., Ferenci, P., Gschwantler, M., Wedemeyer, H., Berg, T., Spengler, U., Weiland, O., van der Valk, M., Rockstroh, J., Peck-Radosavljevic, M., Zhao, Y., Jimenez-Exposito, M.J., Zeuzem, S., Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut, 2016, 10.1136/gutjnl-2016–312444.
289. Wilder, J.M., Jeffers, L.J., Ravendhran, N., Shiffman, M.L., Poulos, J., Sulkowski, M.S., Gitlin, N., Workowski, K., Zhu, Y., Yang, J.C., Pang, P.S., McHutchison, J.G., Muir, A.J., Howell, C., Kowdley, K., Afdhal, N., Reddy, K.R., Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology 63 (2016), 437–444.
290. Wilfret, D.A., Walker, J., Adkison, K.K., Jones, L.A., Lou, Y., Gan, J., Castellino, S., Moseley, C.L., Horton, J., de Serres, M., Culp, A., Goljer, I., Spreen, W., Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob. Agents Chemother. 57 (2013), 5037–5044.
291. Wilson, E.M., Kattakuzhy, S., Sidharthan, S., Sims, Z., Tang, L., McLaughlin, M., Price, A., Nelson, A., Silk, R., Gross, C., Akoth, E., Mo, H., Subramanian, G.M., Pang, P.S., McHutchison, J.G., Osinusi, A., Masur, H., Kohli, A., Kottilil, S., Successful retreatment of chronic HCV Genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin. Infect. Dis. 62 (2016), 280–288.
292. Wong, K.A., Xu, S., Martin, R., Miller, M.D., Mo, H., Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Virology 429 (2012), 57–62.
293. Wyles, D.L., Rodriguez-Torres, M., Lawitz, E., Shiffman, M.L., Pol, S., Herring, R.W., Massetto, B., Kanwar, B., Trenkle, J.D., Pang, P.S., Zhu, Y., Mo, H., Brainard, D.M., Subramanian, G.M., McHutchison, J.G., Habersetzer, F., Sulkowski, M.S., All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection. Hepatology 60 (2014), 56–64.
294. Wyles, D., Pockros, P., Morelli, G., Younes, Z., Svarovskaia, E., Yang, J.C., Pang, P.S., Zhu, Y., McHutchison, J.G., Flamm, S., Lawitz, E., Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 61 (2015), 1793–1797.
295. Yang, H., Robinson, M., Corsa, A.C., Peng, B., Cheng, G., Tian, Y., Wang, Y., Pakdaman, R., Shen, M., Qi, X., Mo, H., Tay, C., Krawczyk, S., Sheng, X.C., Kim, C.U., Yang, C., Delaney, W.E. IV, Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob. Agents Chemother. 58 (2014), 647–653.
296. Yang, S., K RJ, Lim S., Choi, T.G., Kim, J.H., Akter, S., Jang, M., Ahn, H.J., Kim, H.Y., Windisch, M.P., Khadka, D.B., Zhao, C., Jin, Y., Kang, I., Ha, J., Oh, B.C., Kim, M., Kim, S.S., Cho, W.J., Structure-based discovery of novel cyclophilin a inhibitors for the treatment of hepatitis C virus infections. J. Med. Chem. 58 (2015), 9546–9561.
297. Yi, G., Deval, J., Fan, B., Cai, H., Soulard, C., Ranjith-Kumar, C.T., Smith, D.B., Blatt, L., Beigelman, L., Kao, C.C., Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob. Agents Chemother. 56 (2012), 830–837.
298. Younossi, Z.M., Park, H., Gordon, S.C., Ferguson, J.R., Ahmed, A., Dieterich, D., Saab, S., Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am. J. Manag. Care 22 (2016), SP205–211.
299. Zeuzem, S., Soriano, V., Asselah, T., Bronowicki, J.P., Lohse, A.W., Mullhaupt, B., Schuchmann, M., Bourliere, M., Buti, M., Roberts, S.K., Gane, E.J., Stern, J.O., Vinisko, R., Kukolj, G., Gallivan, J.P., Bocher, W.O., Mensa, F.J., Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369 (2013), 630–639.
300. Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H., Illeperuma, A., Svarovskaia, E., Brainard, D.M., Symonds, W.T., Subramanian, G.M., McHutchison, J.G., Weiland, O., Reesink, H.W., Ferenci, P., Hezode, C., Esteban, R., Valence Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 370 (2014), 1993–2001.
301. Zeuzem, S., Berg, T., Gane, E., Ferenci, P., Foster, G.R., Fried, M.W., Hezode, C., Hirschfield, G.M., Jacobson, I., Nikitin, I., Pockros, P.J., Poordad, F., Scott, J., Lenz, O., Peeters, M., Sekar, V., De Smedt, G., Sinha, R., Beumont-Mauviel, M., Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 146 (2014), 430–441 e436.
302. Zeuzem, S., Jacobson, I.M., Baykal, T., Marinho, R.T., Poordad, F., Bourliere, M., Sulkowski, M.S., Wedemeyer, H., Tam, E., Desmond, P., Jensen, D.M., Di Bisceglie, A.M., Varunok, P., Hassanein, T., Xiong, J., Pilot-Matias, T., DaSilva-Tillmann, B., Larsen, L., Podsadecki, T., Bernstein, B., Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370 (2014), 1604–1614.
303. Zeuzem, S., Ghalib, R., Reddy, K.R., Pockros, P.J., Ben Ari, Z., Zhao, Y., Brown, D.D., Wan, S., DiNubile, M.J., Nguyen, B.Y., Robertson, M.N., Wahl, J., Barr, E., Butterton, J.R., Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann. Intern Med. 163 (2015), 1–13.
304. Zeuzem, S., Soriano, V., Asselah, T., Gane, E.J., Bronowicki, J.P., Angus, P., Lohse, A.W., Stickel, F., Mullhaupt, B., Roberts, S., Schuchmann, M., Manns, M., Bourliere, M., Buti, M., Stern, J.O., Gallivan, J.P., Voss, F., Sabo, J.P., Bocher, W., Mensa, F.J., SOUND-C2 Study Group. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Antimicrob. Agents Chemother. 59 (2015), 1282–1291.
305. Zeuzem, S., Mizokami, M., Pianko, S., Mangia, A., Han, K.H., Martin, R., Svarovskaia, E., Dvory-Sobol, H., Doehle, B., Hedskog, C., Yun, C., Brainard, D.M., Knox, S., McHutchison, J.G., Miller, M.D., Mo, H., Chuang, W.L., Jacobson, I., Dore, G.J., Sulkowski, M., NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J. Hepatol., 2017, 10.1016/j.jhep.2017.01.007.
306. Zhang, N., Zhang, X., Zhu, J., Turpoff, A., Chen, G., Morrill, C., Huang, S., Lennox, W., Kakarla, R., Liu, R., Li, C., Ren, H., Almstead, N., Venkatraman, S., Njoroge, F.G., Gu, Z., Clausen, V., Graci, J., Jung, S.P., Zheng, Y., Colacino, J.M., Lahser, F., Sheedy, J., Mollin, A., Weetall, M., Nomeir, A., Karp, G.M., Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. J. Med. Chem. 57 (2014), 2121–2135.
307. Zhong, M., Peng, E., Huang, N., Huang, Q., Huq, A., Lau, M., Colonno, R., Li, L., Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor. Bioorg. Med. Chem. Lett. 26 (2016), 4508–4512.
308. Zhou, L., Zhang, H.W., Tao, S., Bassit, L., Whitaker, T., McBrayer, T.R., Ehteshami, M., Amiralaei, S., Pradere, U., Cho, J.H., Amblard, F., Bobeck, D., Detorio, M., Coats, S.J., Schinazi, R.F., beta-D-2'-C-Methyl-2,6-diaminopurine ribonucleoside phosphoramidates are potent and selective inhibitors of hepatitis C virus (HCV) and are bioconverted intracellularly to bioactive 2,6-diaminopurine and guanosine 5'-triphosphate forms. J. Med. Chem. 58 (2015), 3445–3458.
309. Zhu, H., Wong-Staal, F., Lee, H., Syder, A., McKelvy, J., Schooley, R.T., Wyles, D.L., Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J. Infect. Dis. 205 (2012), 656–662.